aie wae REPORT OF The Committee on Drugs and Pharmaceutical | Industry (Hathi Committee Report) 1975 MINISTRY OF PETROLEUM & CHEMICALS GONE OF INDIA Apri. 1975.cuvene 1 Cuvee Cuseren Cuweren (V cuenn Vv Carn Ort Cusenmyytt Cswrie VL Cuore 18 Cusp X Cuserie XI costes Provgrev musle an sans aeieved Wy a = Develonment of the Drug Industry and the Indian Sector Raw materials for ball drag mvanuactire Development and Flaw of Techashog Poe Pricing of leas aad Phasinacsaticsls akty Control of does 7 ersures for proviting essential druss and common household eematies to the general sublic expesial I teas an abolitian of brand wanes far des i. Conclusion and aeknostesconsat IMorpacis — to sinss Saoss ko-ias Hott ten sa22CHAPTER | INTRODLE TION c fianetioning and growth of the Drugs and. Phy sears wei engaging the attention of Government for quite sometime, parsiculerly with « view to finding out wand means to meet the growing requirements and broad social objectives before the country. Questions about ‘us performance of the public sector units, multi-national firms’ gaining stronghold in this field, prices of locally produced medicines ‘etc, were raised in the Parliament, Following a suggestion made in the Parliament, the Government of India in the Ministry of Petroleum and Chemicals, set up a Committee by a Resolution No. 3 26)/73-Ch. Ill dated the Sth Feb- ruary, 1974, consisting of the following members :-— Hiigal Industry in India over the pas 2. Shri Jaisukhlal Hathi Chairman 2. Shri Yashpal Kapur, M.P. Member 3. Shri Vasant Sathe, M.P. . 4, Dr. Ranca Sen, MP.” D 5. Shi K.S, Chavda, M.P. 6, Shri C.M. Stephen, M.P. 7 7. Dr. ML. Dhar, Director, Central Drugs Research Institute, Lucknow. 8. Dr. B.D, Tilak, Director, National Chemical Laboratory, Poona. 9. Shri SS. Maraths, Chairman, Bureau of Industrial Costs & Prices. » 10, Shri Vinod Kumar, Joint Secretary, Ministry of Petroleum & Chemicals. . 1. Shri PS. Ramachandran, Drugs Controller, D.G.H.S. . 12. Dr. B. Shah, Dy, Dirzctor General, D.G.T.D, . » 13. Dr. BL. Ranga Rao, Centre for Studies in Sciencs Policy, Jawaharlal Nehru University. Shri M.K. Rangnekar, Commissioner, Food and Drug Administration, ment of Maharashtra, Bombay, . Dr, P.R, Gupta, Adviser (Drugs), Ministry of Petroleum & Chemicals Govern. Member-Secrousry. 2. The Government of India appointed the above Committee tw go into the various facets of the Drug Industry in India with a view to promoting growth of the Drug Industry particularly of the indian and small. scale sectors improve technological develorment, take effective Quality Control n:casures on drugs, reduce the prices oF medicines. as well as {0 rationalise the prices tructure, provide essential drugs throughout the country, and make available raw materials to the industry particularly to the small- cctor. ete. Appointment of such a Committee was also felt necessary in the context of the large-scale expansion of the drug and pharmaceutical industry envisaged during the Fifth Five Year Plan period, with a view to ensuring the regulated and rapid growth of drug manufacwure, The terms of reference were as under :— status achieved by it, public sector attains @ leadership role in the nd development. (i) To enquire into the progress made by the industry and th Gi) To recommend measures necessary for ensuring that th. rch manufacture of basic drugs and formalations, and i ii), To make recommendations for promoting the rapid growth of the drugs industry and, particularly, of the Indian and Small Scale industries Sector. In making its recommendations the Committee will Keep in view the need for a balanced regional dispersal of the industry. (iv) To examine the present arrangements for the flow of new technology into the industry, and make recemmen- dations therefor. y control of drugs, and for rendering assistance to small-scale" (¥) To recommend measures for effective qualit units in this regard.2 (wi) To examine the mousures taken so far 10 reduce the prices of drugs for the consumer, and to recommend further mewsures as may be necessary to rationalise the prices of basic drugs and formulations. fia) To recommend measures for providing essential drugs end common house-hold remedies 1c the general public, gupcentlly ia he runs! areas. (sun Fo resommend institutional and other arrangements to casure equitable distribution of basic drugs snd raw avuterials especially’ to the Small Seale Sector sat Resolution sotting up the Committe is at Annexure 1. At the mecting held on 21st Murch, 1974, the Committee coopted Dr. B.B. Gaitonde, Director, HafTkine Institute, Bombay. Shri PS. Ramachandran, Drugs Controller (India) retired from Government service but con- tinued as a Member of the Committee. On'the advice of the Minister of Health and Family Planning Dr. S.S. Gothoskar, who succeeded as Drugs Controller (India) was coopted as i member in the meeting held on the Sth January, 1975. 4, Tas fivst mosting of the Com nites was hold on the 6th March, 1974 wherein during the course of discussion 4 Sub-Committse consisting of the following m.mbers, Was sct up to examine the question of issue of Permission/ No objection Lettzrs and C.0.B Licences by Government 1. Shri K.S. Chavda, M.P. Dr. Ranen Sen, MP. 3. Dr, BV. Ranga Rao 4. Sei B.S, Ramachandran Convenor Shei Jaisukhital Hathi as Chairman attended the meetings. 5. At the second meeting held on the 21st March; 1974 the Commitiee finalised the various questionnaires for issue to the various Organisations ete. A copy of each of the Questionnaires prepared and issed to the units in the Organized Sector, Associations representing the Drag Industry, Indian Medical’ Associations and other Specialists’ Organisations in the medical eld is at Annexures HIV. Subsequently, another Questionnaire was also issusd to the State Govern their views/suggestions (Annexure V). 6. While the work of the Committee wats in progress an unfortunate and tragic incident took place in Kanpur following administration of a Transfusion solution to some patients in a Hospital resulting in the death of some Feisons, As the question of quality ef the medicine used was involved in this incident, both the Government and the Commities felt that the question of quality control should be examined on a priority basis. Following the advice of the Ministers of Health & Family Planning and Petroleum & Chemicals, the Committee took up the term of reference, namely, “to recommend measures for effective quality control of drugs and rendering assistance to, the tiall-scale units ir. this regaed™, for immediate examination and to report to Government. A. Sub-Commitice ¢ of the following members was appointed on 2nd May 1974 to go into this question thoroughly and ex- consi peditiously :— 1. Dr. Ranen Sen Dr M. L, Dhar Shri M. K. Rangnekar 1. Dr. BB, Gaitonde Dr. B. V. Ranga Bao Shri PS, Ramachandran Convenor The report of the Sub-Committee was considered by the Committee on Drugs and Pharmaceutical Industry on the 16th May, 1974 and the report was submitted to Government on 25th May, 1974. The report is incorporated” as Chapter IX of this report. 7. With a view to obtaining first hand knowledge of the operations undertaken by the various sectors of the Drug Industry and particularly to assess the problems faced by the Indian sector in expanding their drugs manue facturing activity and also to obtain. the views of the manufactururs and Associations/Organizations of drug manu-, facturing units, the Committee undertook a tour to Maharashtra & Gujarat in June-July, 1974 and. visited some drugs and pharmaceutical manufacturing units both in the organised as well as the small-scale sector of the industry. The Committee also held discussions with the Local Associations/Organizations of the drugs znanu- Yacturers, to obtain their views on the various aspects involved and particularly as to how this industry could grow to meet the requirements of the country and also to assess the posiblliles/potentaliy ofthe Indian sector to devslop at a faster pac3 hin August, 1974, Hyderabad and Madras in September pur in November 1974, In Pimpri, Rishikesh and Hyderabad, jindustan Antibiotics Limited, Antibiotics Phints and Synthetic 8, The Committee made similar visits to Rish 1974, Calcutta in September, October 1974 and Di the Committe: visited the public sectof units namely Drugs Plante of the Indian Drugs and Pharmaceuticals Limited, 9, Resides visting the dig manuficturing, large and small scale units, situated at the various places. the Committee met the representatives of the Associations at ombay. Baroda, Alimedabad, Caleutta. Mfaday and Fiyderabad, "it also visited the Research centres of Ciba-Geigy, Sarabliis and Bengal Inmynity. separaetiy. The Commitee also met the representatives of-Greanisaion of Pharmaceutical Producers af Indie D-"slopment Council of Drugs and Pharmaceuticals, Indian Drugs and Pharmaceuticals ‘Limited, ‘State Trading Corporation, and the Indian Medical Association. The names of the manufacturing units visited by the Committee and those of the various ‘Associations with whom discussions were held along with the dates, are shown in Annexure VI 10. The Committee during the course of discussions, particularly on the question of making the esecntial medi- cines available in adequate quantities to the wider section ‘of the people inciuding those in the rural areas, felt that a list should first be drawn up to identify the essential medicines which are required to be produced in large quantities for mass consomption. It considered that although the question of substitution of brand names by generic names in respect of the medicines marketed by the Industry was not specifically mentioned in the terms of reference for this Committee, the subject followed clearly from the other terms of reference such as reduction/rationalisation of prices of formulations for the consumers, niaking essential dregs available in larger quantities 10 the general public ete ‘The Committee, therefore, appointed a pane! consisting af some of the members of the Committee and Specialists in the medical ficld. from all over the country. The panel consisted of the following members. :— 1. Dr. Ranen Sen, Member of Parliament, 2. Dr. A. B. Chowdhury, M.B.. PH.D, FA.M.S., F.N.A.. Ditector, Calewttt School of Tropical Medicines Chittranjan” Avenue, Cateutta-12. 3. Dr. S. Padmavati, Director-Principal, Maulana Azad Medical College, New Delhi 4. Dr. B. Ray Chaudhury. M.D. (Cal.) FRCP, Ph.D. (Edin), Associate Professor of Medicine, Institute of Post Graduate Medical Education and Research, 22-Lower Circular Road, Caleutta-17. 5. Dr. K.V. Thiravengadam, B.Sc., M.D., FAMS, Professor of Medicine and Vice Principal, Stanley Medical College, Physician, Government Stanley Hospital, Madras. 6. Shri P.S. Ramachendran, Drugs Controller (india), D.G.H.S., New Dethi. 7. Dr. K.G. Nair. MD (Bombay) Ph.D. (Chicago) FACC (U.S.A.) FICA (U.S.A). af Ditector-Professor of Medicine, Head Department of Cardiology and Radio-lsotope Unit, KEM lospital and Seth G.S. Medical College, Bombay. 8. Dr. BJ, Vakil. Hony. Professor, Gastroenterology, Grant Medical College. Hospital, Bomb:iy. 9. Dr. B.B. Gaitonde, M.D.M.Se. (Med.), FA.Se. Director, HalTkine Institute, Bombay. Convener Dr. P.R. Gupta and Shri M.K, Rangnekar assisted the panel in its work. IL, The terms of refeence for this panel were as follows :-— (i) To recommend measures for providing essential drugs and common house-hold remedices to the generat public especially in the rural areas, and (ii) whether it would bc in the national interest to substitute brand names by generic names and if so, the manner and extent to which it should be done, The Panel submitted its report on the 29th June, 1974, which was considered by the Committee on 25th July, 1974 and ist and 42nd January. 1975. The report as modified and adopted by the Commitice was sent 10 Government on the 21st February, 1975. This constitutes Chapter X of the Report. 12. The schedule of the programme of the Committee including its sittings on the Sub-committees, meeting the representatives of the Associations at Delhi are also shown in Annexure VI. 13. The time for submission of the report was extended up to 7th February, 1975 and later upto Jth Apri 1975.by Government Resolutions No, 326)/73-Ch, IM dated the 23rd August, 1974 and Sth February, 191s aes pedlively. 14. The Committee has tried to collect the data and statistics of production, capital invested, turnover, ete., from authentic sources and wherever possible, based on replies given in tie Parliament. These may be taken as indicative and not exhaustive,ANNEXURE {Chapter Hara 2) TO BE PUBLISHED IN PART U—SEC. 3—SUB-SEC. (ii) OF THE GAZETTE OF INDIA—EXTRAORDINARY No. 3(26)/73-Ch. U1 MINISTRY OF PETROLEUM & CHEMICALS New Delhi, the 8th February, 1974 Resolution - Subjects—Constitution of Committee on the drugs and pharmaceuticals industry. In the context of the large-scale expansicn of the drugs and pharmaceuticals indutsry envisaged during the Fi Five Year Pian, with a view to ensuring the regulated and rapid growth of drugs manufacture, and further with a ve to ensuring that all essential durgs are made available to the consumers at reasonable prices, Government have decide to constitute a Commitice with tie following membership :— 1. Shri Jaisukhlat Hathi, M.P. 2. Shri Yashpat Kapur, M.P. 3. Shri Vasant Sathe, M.P. 4. Dy. Ranen Sen, M.P. 5. Shri KS, Chavda, M.P. 6 4 8. Chsirman Member 5. Shri CM. Stephen, M.P. ; Dr. M.L. Dhar, Director, Central Drugs Research Institute. Lucknow. tory, Poona, Dr. B.D. Tilak, Director, National Chemical Labora 9. Shri SS. Marathe, Chairman, Bureau of industrial Costs & Prices. 10. Shri Vinod Kumar, Joint Secretary, Ministry of Petroleum & Chemi IL, Shri P.S, Ramachandran, Drugs Controller, DGHS 12. Dr. B. Shah, Dy. Director General, D.G-T.D. 13, Dr. BLY. Ranga Rao, Cente for Studies in Science Policy, Jawaharlal Nebr Unie versity 14, Shri MLK. Rungnekar, Commissioner, Food and Drug Administration, Government of Maharashtra, Bombay. 15. Dr. P.R. Gupta, Adviser (Drugs), Ministry of Petroleum & Chemicals. . Member-Secretary 2. The Committee will examine and report upon the following matters + (8) To enquire into the progress made by the industry and the status sichieved by it. (ii) To recommend measures necessary for ensuring that the public sector attains a leadership role in manufacture of basic drugs and formulations, and in research and development. (ii) To make recommendations for promoting the rapid growth of the deugs industry anc Indian and small scale industries sector. In making its recommendations the Committee will keep in vi the need for a balanced regional dispersal of the industry (iv) To examine the present a:rangements for the flow of new technology into the industry, and make re mmendation therefor. (¥) To recommend measures for effective quality control of drugs, and for rendering assistance to small se units in this regard, (vi) To examine the measures taken so far to reduce the prices of drugs for the consumer, and to recomn: such further measures as may be necessary to rationalise the prices of basic drugs’ and formulatior (vii) To recommend measures for providing essential drugs and common house-hold remedies to the gen public, specially in the rural arcas. ;(iti) To recommen institutional and other, arrangements to ensure equitable distribution of basic drugs and raw materials especially to the Small Seale Sector. 3. ‘The Committe sill asserttia and take into consideration the views of the State Governments end other intcrests coneenred, ay may be found necessary. headquarters will be at New Delhi. 4 The Committee's 5, All Secretariat assistance required by the Committee will be provided by the Ministry of Petroleum and Chemicals. 6. The Commitice will mect as often as may, be considered necessary by the Chairman and shall submit its final report to Government within six months. The Committee may also, at its discretion, submit interim reports fon specitic matters from time to fime. Sd/- (PK. DAVE) Secretary to the Govt. of India ORDER Ordered that this Resoultion be communicated to all the Ministries of Government of India, all State Govern. ments, the Comptroller & Auditor General of India, Accountant General, Commerce, Works & Miscellaneous, and Accountant General, Central Revenues. Ordered also that the Resolution be published in the Gazette of India for general information, Sdj- P.K. DEVE, Secretary of Govt. of India.ANNEXURE IL Questionnaire to Now dhtegs cs deine Coweties Rules) sth Ue list ve Seats aed (el eter nae pt seston) of each of diese drags TC) (Pd and fe) produced 9 macopoeial products and ths saluc [east to the 6 you during your fist financial soar Hactused a» 1952 and those manufactured subsequent reture has undertaken, ely the drugs whiess sur ns 2. Aiease fist oun se inst whieh the expansion in manuly quoting the Government authority 3. Have you any produets licensed to be manufactured under the Industries (Development and Regulation Act 19St and whose manufacture has nor been commenced by you ? Iso. please list chose products with capacities, | fed hy you ? Please specify such product of products other than drugs whieh are m hends = “4. What is the ra nial year under the followis and their turnover for your last fina (4) Laboratory chemicals (b)_ Cosi fe} Insecticides and Pestivitles tw) Nuw fe) Confectionary items 4) Other fems 18 Guring Your last Hinaneiat vear™ ely on the follos 5. What is the amount of money spent by you sepa 8) Orfice establishment (b) Finance and Accounts Department (e) Planning and Development (@) Sit Promotion (excluding expenditure covered under 6 and 7 below} (c) Product development (f) Product of Drugs (g) Quality control (hy Research (i) other heads. 1h of the field force of matical representatives employes by yous an tet74 the annus 6, What is the st expenditure thereon les promotion vepresentatives employed bs you on F174 fe Jb of the field foree of 7, What is the strom: non-drug items and your ust expenditure thereon ca Briel resume of thy niaure of the research aetivitis ns AS result of your feseareh in this country, Whe manufactured by you in this country? 8. Have you any resear Spent on Fes, firms by geting i Hite raw-material ued by them? 1F so, please supply details with th issising the _mediv 9. Hare you been F formulations. men harmaceutical aids or pharmaceuti ames and saddresses af firms 50 assisted, of your import ficence und rnings during the sine pet 10, What is the val the value of your export value of excl under the 1TC ree nittances eyady by you during 1973-74 towards (a) profit for a foe 1d} scieniitic contribution and (e) other heads, TL, What is the extent of foreign evel foreign eqtity holders (b) patent sosatties (€1 know hor: se stitte whether saw have apted for compliance with part 7 of the Drugs (Priges Control) Order 1 ressive sales turnover during each of your last diree compa, 12, Ph or para 14. In the katter case, what ins been your pro: Seaes and tne dividends deslared by you for those Sears ny suggestions to ofler to make the Patents Act more useful to the drug industey in this countr: 13, Have you 14, Are you satisfied with the quality control measures over drugs taken by the Central and State Drug Cont improvement in this connection ? Is there adequ: you any suggestions to make for Control Administration and the Industry Administrations ?H rapport between the Di 67 15. In what way does the industry eaonsente with the Drug Control Administration in tackling spurte mf in what manage can Government's clfnris i thi directiew bye tightened tnareed aly Fred ns tes Hoop ge corre Sasugtns 1 pe ef phissiciams sad are a Pass feet Goo lolslef pe duct ta the Pave ote gow vies on the abuhtion oF Iigd Maney ok ds tye 2H tated alvalition is nat eomédered Fram thee tye of bial ames fhe reviricted 17, Sampling of drags by manufacturers tw the medical profession it is reported leads to mal: ent tenes. Whit will he's on to stoping the disteipution of suet samples 18, What are your views on (a) the need te avoid multiplicity of drug formullations of the same com (b) combinations of drugs and the need to prohibit ircitional and inefieetive combinations (c) the desi feduicing the number of vitamin preparations to the absolute minimum and (d) prohibition of advertise in the lay press. in the public and through other audio-visnal medi. ? the development of the drug indus 49, What role do you expt the public sector concerns play the next 10 years 2 ' " 20. Are you satisfied with the perform materials? In what way can tte work es of the STC and IDPL as catmtising agencies for dist is 2 of nese organisations be improved ? ents at the Centre, namely, the Ministry of Petroleum & Chere isots aniston hefpful and prompt in their dealing with the industry 2M. Are the Government dy GTD and the Centeal Drug Contral O} sof the names of such Companies znd the Do you own any other company 2 Ws. g ined by each of them 23. Hay products manut YOu any associated companies 7 IF So, give particulars of the names of such companies sad the fuetuted by exch of them, 24. Do you think that in any particular ease the country » resources are being wasted in obtaining technical know-how from abroad when it could have been developed indigenously with proper planning and a we Drugs (Prices Control) Order 1979 has been welcomed by the general public, Without detracting- From the essential features of this order, have you any suggestions to make for simplifying the implementation prow dure under this Order ? wh public. éspeci durgs and common household remedies to the generat iy. a reasonably cheap prices Ht measures do you suggest for providing esser lly’ in the rural areas and to the weaker sections of the commun 2°. What_mes meet the quuntiv so the production of drugs and pharmaceutical products «0 as to ures do sou suggest 10 ine? a the enc of the Fifth Fise Yeor Plan. ive reairement ob the counts equity, please furnish the information alse Fur the ques= 28. In ease your eompany has more than 26%, Fore tions covered by the enclosed statement separately, Statement referred tin Question No, 28 1. Kindly supply photostat copies of s—= fay Industrial Licences for drugs secures under the Industries (Development and Regulation) Act 1951. (by Permission/No objection letters granted by the concerned suthor © (2) Applications made tr COB ligences and ved from Government Applications for diversification ane replies re licences issued by Government 2. Please supply information ats to the dates on which manufacturing lieences under the Drugs and Cosmeties Act were eramted for the items covered hy COB licences granted t0 you. 3. Please supply details about the foreign personnel employed by you during the last five years together with particulars of the salaries/honararium and perquisites paid to them, 4. Please supply copies of your Balance Sheets for the last five years. 5. How many products are marketed by you under brand names ? 6. How many drug patents have been sealedjare under registration by your principals in this conutrywo and hhow many of thee patens are be ed BY Your inthis country? YM of Pet, & Chem/75—2 :ANNEXURE It QUESTIONNAIRE IT (Chapter 1—Para 5) a Lens sete A owciation views on the ante 99 fi phayct by the madam and smatlewale ster sate i wruvdatelopinent What role de you envisage fF thew sectors ie the Faniire devehopmeni of the ing tts sion that big firms, particulaily the foreign ones, have se ar male the mofar contre sie indusery, Do you agree with ahis view ? Give reascns, 2. What are the handicaps that hamper the development of the medium and smratl-ccale seetare especially iv attaining the ratve capacities of production ? Ptcase specily in terms of :~ (2) Raw material supplies, (b) Packaging materials, (c) Import of Machinery, laboratory chemicals ancl equipment, (d) the Patents Act (¢) New Drug clearance, (¢) Manufacture of basic drugs. (g) Import sus titution, (h) Export, () Financial resources, (j) ITC Regulations and procedures, and ¢k) any other aspects. 3. Do you suffer from the disability of obtaining sufficiently qualified (echnical personne! for manufaentring your products ? 4. Testing facilities, product development, sales promotion techniques, dissemination of technical information about drugs to doctors, professional management, planning for future development these aspects, it is said ure not given sufficient importance by the small and medium scale sectors of the industry. What are your views on the observations al your suggestions to improve the performance of your member firms in this regard ? In whit Sas cc Government assisi the industry in these fields? 5. In the context of the development profiles that have been prepared for the drug industey over the neAt 10 ars. what contributions can the medium and small-scale sectors of the industry make ? G. What sacasuves to do you suggest to increase the production of drugs and pharmaceutical products s+ 23 to meet the quantitative requirements of the countey at the cud of the Fifth Five Year Plan ” 7. Big firms, as they expand production of bulk drugs, can encourage small and medium scale firms by’ assis: ting them with the know-how for development of intermediate raw materials, pharmaceutical aids, etc. Have you xny views on this point, parheularly as to kow big firms can be persuaded (o help the small-scale and medium-scale firms ? 8. The Price Control Order in sespect of drugs has been welcomed by the general public. What is the impact of this Onder on the medium aul small-scale sectors ofthe industey ? Without detracting (rom the essential featses off the Price Contra Order, have you any suggestions to make for simplifying the implementation procedures unger this 9. Ais said that the prices of drugs could be maintained and even lowered ifdeug firms can diversify into areas sited aS nutritional products, laboratory chemicals, cosmetics, veterinary preparations, insecticides, etc, Has your Association spesific idea on these aspects particularly in regard to the potentiality of the firms in the smal and medivm- tors ? Can the Government (Central & State) assist in any way ? 10. Iu what manner can the meditim and small-scale firms promote deug research ? Do you think that the facili- ties for rescureh and development in the fields of Fine Organic Chemicals and Microbiclogy are adequate for the 7e- quirements of the small and medium seale sector of the industry And what assistance do these firms expect from ‘Government in this regard ? What are your view on having rexional research laboratories with government subsid'ary ? IL, Are you satisfied with the quality control measures over drugs taken by the Central and State Drug Control Administrations Have you any suggestions to make for improvement in this connection? — Is there adequate rapport between the Drag Control Administration and the industry? 12. In what way does the industry cooperate with the Drug Control Administration in & and ia what munaer ean Government's efforts in this direction be tightened? ckling spurious drug 13. The medical profession in India, itis generally reported is not favourably disposed towards drugs manu factured by the medium and small-scale sectors of the industry vis-a-vis those marketed by big companies and foreign companies. What steps do members of your Association propose to take to win the confidence of the medical pro: fFessina wat to eaavince tiem of the quality of drugs marketed by your member firms? 8fo, 14, Drugy marketed ander brand names are generally expensive. Brand names influence the presor nid are used as a lever to boost the sales of their products hy big. firms. particuletl he Face of these facts, wit ave the views af your Asscciation on the aboliiion oF beand iv tal consideree aulvivabls, to What exsent Gai tse use of t Mews ef your \oasiatien sis carthe ss Lcoaneid mubipliey of Ji ag tocmumation es ite ive combinations (¢) the desicabils ment of el the need to ppralibit irrational and ile tions to the absolace minimum and (cl) prohibition of ah oti audi ea) msdn () Conbintions of dr tof reducing the numer oF vitamin prepa drugs in the hay pre in the pucblig sina thew 16, Distribation of samples of drags by manutacturers to the medisal profession it is reported, lee to male of dilfersnt types. Wirat will be the reaction of your Association to stopping the distribution ol'such simples? 17, Waat role does your Association expect the public sector concerns to play ? ie IS. Are you sttified with the performance of the STC and IDPL as canalising agencies for distribution of rav~ materials ® Do sou think that the system of allotment of canalised raw-malerials and indigenously manufecturcd bulk rags requires siny modification to augment the supply of these items tothe puerly Indian sector of the incostey particularly te small ane meditim sector ? he what way ean the working of these organisations be imptcvee ? 19, Aro the Goverment departments at the Centre, namely, the Ministry of Petrcloum DGD nd the Central Drug Control Organisation helpful and prompt in their dealing with the ind 2U. What measires do you suggest for providing essent petal public, expecially in the rusal areas and to the weaker sections of the community, at re Ul drugs and common hicuschold remedi soni.bly chesANNEXURE IV QUESTIONNAIRE 1 (Chapt 1. What is your general impression about the drug industry in India and its performance tPara 5 2. Has the industry satisfied your expectations in regard to the range of drugs eflered by it ? In gen. b sae tie drugs marketed by the indusiry useful to the medical profession or of the type which could be considered ay “money spinners” ? y 3. Had your Association any observations to make on the quality control aspects of the drug industry in this ‘country in general and with special reference to 7 (a) the multi-national firms operating in this cozntry (such as CIBA-GEIGY, Glaxo, Boots, Sandoz, Cyznamid, Phizer, e.); (b) the big firms of the Indian sector (such.1s Mlembics, Bengal Immunit 'y, Unichem, Sarabhai et.); and (c) the small-scale sector in the drug industry ? 4. In the opinion of your Assaciation, are drug prices beyond the reach of the common min? Does any sector of the drug industry or do sny categories of drugs deserve special mention in this connection ? 5. 1s the medizal profession “baffled” by the multiplicity of the same type of preparations ? Iso, can your Association suggest any solution for this problem ? : 6. One way of minimising the multiplicity of drug formulations could be through wide-spread u profession of the National Formulary of India published by the Ministry of Health. in the Gover nd with which representatives from various medical associations have been associated. Dees your Associction feel that the National Formulary of India lias been put to proper use by the Medical profession ? One of the criticisms voiced is that this Formulary is biased towards use by doctors in Goverment hospitals and that the prescribing practices of the physicians outside hospitals have not been given adequate consideration. Has your Association any suggestions for the improven.ent of the National Formulary ? 7. What is your Association's view on combination af drugs? Would you like any specific category of combi nations to be prohibited ? 8. What is the view of your Assosiation on the usefulness of the vitamin products marketed by drug manu fucturers ? Is there any ssop2 for restricting or regulating their number ? 9. Drugs marketed under brand names are generally expensive. Promotions of brand names, itis stated, ine terferes with the prescribing practices of physicians. Further, brand names are used as a lever to boost the sale af products, In the face of these arguments, what is your Association's views on abolition of brand names of drugs ? If total abolition is not considered advisable at this stage, what steps Would you suggest for progressive abolition of such names ? 10. There is criticism about the drugs being advertised :— (a) through the All India Radio. (b) in the lay press, and 5 (6) in streets, cinem houses, ete should advertisement of drugs through these media be prohibited or regulated in any sp je manner ? 11. Scripts relating to advertisement of drugs broadcast through the All India Radio are at present screened by a Comniittee which includes a representative of the Indian Medical Association. Mas your Association any sugges- tions to make for more steingent screening of advertisement so as to prevent false, exaggerated or misleading claims being made ? 10Ir 12. What ts the Association's view on the usefulness of advertisements that are mailed by drug manufacturers to the medical profession ” Since manufacturers include package inserts about the drug is there any need for mailing of fiterature on drugs to doctors, especially as doctors are busy and seldom fine! tims to go through them ? 13, Disiributien of samples of drugs 16 the medicul profession by drug manufacturers. it is reported. way nalysactives of dilferent rype%, Would your Associating suypart shiy prsctice being sapped 2 Wie? sturacce is not esasiend advisable, pase indiate the mamer in whieh distibution of drugs samples could be regul ted ewy on the quality control measures over drugs taken by Government Is there any rapport between your Assoeiation and the Deug Contra! Organisation at the Centre and the Sta Has your Assnciation any views on the improvement of quality contral measures? Would it nat he sotil iPM Associations also arrange for study of drug manufacturing and convey their views to the Drug Control Organisations? 14, What are your Asweiations’ © 15, In the opinion of your Association, what is the extent of prevalence of adulterated and counterfiet drugs in the country ? What remedial measures would you suggest for tackling the problem ? 16, It has boen represented that the dispensaries run by malical practitioners are deficient in the adequacy of arrangements for dispensing operations, the qualifications and experience of the dispensing personnel at the con- dilions of storage of drugs. What are the views of your Association on the dispensaries of medical practitioners being licens wader the Drugs and Cosmetns Rules and subjected tothe ste regulatory measures as Heensed Jrg establishments? 17. Does your Association have specific “Drug Panels” to study the problems rekuting to deugs and the drug industry? “Does the journal of your Association devote itself, among other th subjects. such asthe development of the drug industry: the profits made by drug firms, particularly, Uh n ones: Ure eennomigs af prescribing drugs and the quality control measures observed by drug manufacturing firms? I8. There is an impression that the medical profession generally tilts towards the products of foreign firms and that this is pattly due t6 the high pressure sles promotional methods employed by such firms and the massive sale of sampling of drugs resorted to by them, What is your Association's reaction to this? 19, What mzasuresdo you suggest for providing exseatial Uragsand common houschold remerties to th pubiic, especially in the rural areasand (9 the weaker Sections of the community, at reasonably cheap prices? . What measures di you suggest for increasing the production of drugs and pharmaceutical products s+ a5 to mzet the quantitative reduiremnts of the country at the end of the Fifth Five Year Plan? 21. Does your Assvziatina have any spevitic view on drug research in this country? Do you think the facilities for research and dvelopm:nt in the iiskls of Fine Organic Chemivals and Microbiology adequstie to meet the eountry s requiremzns? Wheat are your views ot having Regional Rescarch Laboratories with Government subsidy” 22. Does your Association havs any observations to make on “New Drugs”. their servening and their eliaicat sin thiscountry?ANNEXURE V Questionusine For The State Govern (Chapter Para 5) 1. What are your views on the quality and availability of medicines produced by = (a) Small-Scale units; (b) Large whotly—owned Indian wi (©) Large foreign coliaborating units; and @) Public-sector units riz. IDPL and HAL. 2, Please indicate in terms of value and quantity the purchases made for State Government hospitals/Dispen- saries etc. from the above four categories of drugs manufacturers, during the last 3 years, separately. 3. What are your purchase policies?. Do you insist on procuring the medicines produced by the weil-known foreign collaborating firms only? Or, have you been switching over from the well-established foreign collaborating. firms to Indian firms’ products, particularly those produced by the public sector units and small-scale firms? If not indigate your reasons. 4. What are your viows about the availability of medicines in general? What measures you would like to sug- gzst to improve the supply/availability position of drugs and medicines particularly in the rural areas? $. What measures do you consider necessary for improving the status of the public sector units, both in the manufacture of bulk drugs and formulations, and other areas like propaganda, distribution of medicines, rescarch and development etc.” 6. What steps, in your opinion, should be taken, for the following : (a) to produce al the bulk drugs in the quantities as required in the country; (b) to promste rapid growth of this industry, particularly the Indian and small-scale sectors, Keeping in \1ew she need for balanced regional dispersal of the indstury;; svsure the availability of ess ia the rural areas; ial drugs and common house-hold remedies to the general public. es- (A) ty sasure equitable distribution of basic drugs and raw materials, particularly for the small-scale sector units 7. Dy yout think the present quality control oa drugs is effective? I not, what measures would you suggest for effective quality control ondrugs and for rendering assistanee to the small-scale units, in articular, in this regard! 8. Wasther any efforts have so far been made for setting up of any drug manufacturing unit under the State eoatcol? IF39, the nam: of such uait along with their detailed activity and sales turnover may be indicated. 9. What measures would you recommend for adoption by the industry to reduce the price of medi the country to the minimum possible level, keeping in view the requirements of funds for its further growth, Research and Development etc.? 10, What are your views about the multidrug formulations as are presently marketed by some of the manu- fucturers?_ Do you coasider that the production of formultations should be limited to those only as given in the National Formulary of India? IL, What are your views on the use of Brand Names? 12, Aay other point to suggest? 12Detail, of sittings of the Committee on Drugs and Pharmaceus various drug manufacturing units, ete, and discussions keld with officials of Government and Associations Organisations, 6th March, 1974, 18th March, 1974. Dist March. 1974 17th April, 1974 29th April, 1974, 2nd May. 1974 ; Bch April, wn} 16th May, 1974 Vth May, 1974 8th Juve. 1974) 9th June. 1974 F 28th June, 1974 Bombay. 20th June, 1974 Bombay ANNENURE ¥E Committces: Lists 10 presentatives of al Industry. and its (Chapter—I—Paras 9 & 12) First meeting of Committee on Drags and Pharmaceutical Industry. Meeting of the Sub-Committee For drafting questionnaires. Second meeting of the Committee. Meeting of the Sub-Committee on Permission/No Objection Letters and C.0.8. Licences. ‘Third meeting of the Committee on Drugs and Pharmaceutical Industry. Mecting of the Sub-Coramittee on quality Cont rol of drugs and related matters. Fourth meeting of the Committee on Drugs and Pharmaceutical Industry. Meeting of the Sub-Committee on Permission Letters. gs of the Medical Panel on essential drugs and abolition of brand names, (Bombay). Visits to , Industrial & Pharmaceutical ixboratoties Limited, Bombay. Mj. Cher Mjs. Abbott Laboratories, Bombay. Mjs. Hoechst Pharmaceuticals, Bombay. Mis, Unique Pharmaceutical Lab., Bombay. Mis. Nitson Laboratories, Bombay. Mis. Sandoz (India) Limited, Bombay. Ciba Research Centre, Bombay. Visits to Mis. Halfkine Instiwete, Parel, Bombay. M/s, Labs. Vifor, Bombay. M/s. Unichem Labs., Bombay. 1330th June, 1974 Bombay Ist July, 1974 Pimpri 2nd July, 1974 Ahmedabad 3rd July, 1974 Baroda 4th July, 1974 Baroda 25th July, 1974, 31st August, 1974 Rishikesh 16th September.1974 Madras, {th September, 1974 Madras. I8th September, 1974 Hyderabad, ‘ 19th September, i974 Hyderabad 14 Meetings with (i) All India Manufacturers Organisation, Bombay Gi) Tadian Drugs Manufacturers Assn. Bombay, (iii) Indian Pharmaceutical Assn., Bombay. Visit to: Mjs. Themis Chemicals, Vapi. Mjs. Themis Orgasyn Chemicals, Vapi. Mis. MAC Labs., Vapi. Visit t0 + Hindustan Antibiotics Limited, Pimpri. Visits 10: Mjs. Cadila Laboratories, Ahmedabad. MS. Gujarat Pharmaceutical and Chemical Works, Ahmedabad, Mecting with Pharniaceutical Mansafacturers Association, Ama: Visits 10: Ms. Alembic Chemicals Works, Baroda Mjs. Vaccine Institute, Baroda. Drug Control Labs., Gujarat, Baroda. Visits to: Operations Research Centre, Baroda. Mjs. Sarabhai Chemicals, Baroda. Sarabhai Research Centre, Baroda, Fifth Meeting of the Committee on Drugs and Pharmaceutical Industry. Visit 10 Antibiotics Plant, Rishikesh. Visits to M/s, Orient Pharma Private Limited. M/s. Mount Mettur Pharmaceuticals Limited. ‘M/s, Tamil Nadu Dadha Pharmaceuticals Ltd. Visits 10 : ‘M/s, Medo Pharma. MS. Citadel Fine Pharmaceuticals Limited. Meetings with Pharmaceuticals Chemical & Allied Manufacturers Association of South India, Joint Council of Indian Pharmaceutical Trade. sto: synthe:ic Drugs Plant, Hyderabad. M/s. Bio-Chemical & Synthetic Products Limited. M/s. Warner Hindustan Limited. Meetings with : Al India Manufacturers’ Organisation A.P. State Board, Hyderabad, Andhra Pradesh. Pharmaceutical & Chemical Manufacturers’ Associations, Visits to: ; M/s. Biological Evans Limited, Hyderabad. M/s. Uni Sankyo Limited, Hyderabad. Discussions with : Minister of Health—A.P, and other Officers.15 sto: M/s. Dolphin Laboratories, M/s. Organon Laboratories, Calcutta. MYs, Bengal Immurity Co., Calcutta a Imanmby Research Instite'e, Calcutta Discussions wil: ® Hon'ble Minister of Health & Family Planning, West Bengal. Courtesy call on Hon'ble Chief Minister, West Bengal Meeting. with All India Manufacturers Ore 30th September, 1974 Caleuita Calcutta inisation, (West Bengal State Board). Ist October, 1974 Cateutia Visits 10: Mis. Smith Stanistreet, Calcutta. ‘M/s. Bengal Chemical & Pharmaceutical Works, Calcutta. Central Drugs Laboratory, Calcutta. Mjs. Dey’s Medical Stores, Calcutta. ‘Mis. Dey-Se-Chein, Calcutta. ‘M/s. Calcutta Chemicals Limited, Catcutta. Meeting with > Indian Drugs Manufacturers Association, and October. 1974 Calcutta Control, West Bengal. i) Speciatists in the ficid of nicdical research, 3nd October. 1974 Calewtta Visits to: Mjs. Accto Chemicals, Cateutta Mj. East India Pharmaceuticals Limited, Calcutta, Mj. Standard Pharmaceuticals Limited, ‘Calcutta. 19th October, 1974 2th Cerober. 1974 Sixth Meeting of the Committee or Drugs and Ph 2st October, 1974 16th November, 1974 Visits 10 + Durgapur. Mjs. Durgapur Projects Limited, Durgapur. ‘M/s. Durgapur Chemicals Liniitsd, Durgapur. Discussions with the Senior Officials of the Undertakings. January n SLAMEE: BEE] sewut ting ot he Connie on Dra and Phone Indy. 20th saruary. 1975 | elated 15} Eighth Meeting of the Committee on Drugs and Pharmaceutical Industry. 22nd January, 1975 Mesting of the Sub-Comimittee on Permission/No Objection Letters etc. Th February, 1975 Meeting of the Sub-Committee on Permission Letter/No Objection Letter/COB Licences with the Secretaries of Ministry of 1.D., DGTD and P & C. Sth February, 1975 Meeting of the Sub-Committee on Permission/No Objection Letters. Sth February, 1975 Oth Februsry, 1975 | Ninth Mecting of the Committee on Drugs and Pharmaceutical Industey. Mth February 1975 1th February, 193 J . 25th February, 1975 4 Tenth Meeting of the Committee on Drugs and Pharmaceutical Industry. 26th February, 1975 f 8 - 4th March, 1975) Sth March, 1975} Eleventh Meeting of the Committee on Drugs and Pharmaceutical Industry. Gth March, 1975. Sth April, 1975 Twallth Mecting of the Committee on Drugs and Pharmaceutical Industry. M of Pet. & Chemy75—3CHAPTER PROGRESS MADE AND STATUS ACHIEVED, by THE PHARMACEUticaL INDUSTRY ‘The drugs and Pharmaceutical industry in India is well established today. It now produces a wide range of drugs including the sophisticated ones like antibiotics, hormones, vitamins in addition to a large number of other thetic chemo-therapeuticals. This industry has an important role to play in maintaining the health of the nation and has the responsibility of meeting the expanding needs of the county. The task before this industry, there fore, is not only to produce more medicines and provide them in the required quantitics but also to ensure that the medicines produced are of the right quality and would relieve the suffering patients of their illness at low cost. 2. The drug needs of the country are diverse and the industry has to meet all such demands. Because of the aiverse nature of the requirements, the industry has to adopt widely diffrent and varied techniques fos the pro: 4 duction of the medicaments.” These covet fermentation technology, synthetic operations, extraction and purife cation of the active principles available in the plant and animal kingdom etc., besides converting these active ingre- dients into the finished formulated dosage form of the right type. Basically this is a highiy research-oriented chemie cal-based industry. 3. It would be worthwhile to trace the history of development of the drugs and pharmaceutical indust in India and the stages it has trekked in achieving the present status. It has a long way to go to achieve the objecti placed before this industry, and indeed, it has to strive hard to make the country self-sufficient 4, Modern system cf medicine embraces a large variety of products ranging from phyto-chemicals. identifiable highly complex chemical substances like antibiotics, hormones ete. A beginning was made in the duction of medicines required under the modern system by starting cinchona plantation in the States of Bengal at Madras, presently known as West Bengal and Tamil Nadu respectively. Factories we set up in the vicinity of 1 plantation areas for the extraction and purification of quinine. Even a brief resume of this chemical-based indust would be incomplete if no reference is made to the poneering work done by Ine Acharya F.C: Ray followed similar efforts of late Messrs T.K. Gaijar, B.D. Amin and Koti-bhaskar. ‘Their efforts. resulted in the establish ‘of units for local manufacture of galenicals and some other simple drugs. Cessation of imports during the first w ‘war years gave impetus to the industry to produce the medicines locally. A new compound, urea-Stibamine, developed through local R & D activity, which was found to be highly effective against Kala-azar, a soourge which afflicting people much those days. The most remarkable success was achieved in the manufacture of Sera. a ‘Vaccines in the period that followed thereafter. Pioneering work in the field of phyto-chemicals was done by la Col. R.N. Chopra. Manufacture of Caffeine from tea-waste, anaesthetics like other form alcohol and a few sit drugs based on coal-tar distillation products were also taken up in the country. In spite of such developments, [progress was far from being satisfactory. During the second world-war, the local industry made further roy by producing # number of other products indigenously out of the locally available raw materials, These were mai in the category of phyto-chemicals, although some progress was also made in the fields of synthetic drugs and bi gical products. The country, by then, produced substantial quantities of Sera and Vaccines. Some industrial ut also took up mnufacture of synthetic anti-dysentery drugs, anti-leprosy drugs and arsenicals. Side by si formulating activities were also increasing considerably based on imported bulk drugs and several new formula ‘were also developed locally. Here again, the bulk of the activity was confined only to the processing of im bulk drugs except for a few items which were produced from late intermediates. The slow progress of the local c industey'atso afected the growth of the pharmaceutical industry. Besides, the appearance of number of syn drugs and antibiotics, which were developed abroad and imported into the country, also tended to change the ‘of drug use in India. Thé medicines that were available out of indigenous production, failed to keep pace with ‘competition offered by the products of imported origin. 5. Inthe year 1953, the Government of India set up the Pharmaceutical Enquiry Committee with the follogl terms of reference -— . 167 (i) To study the working of the existing pharmaceutical manufacturing concemns in India with particular reference to— (4) the demand for the drugs produced and their essentiality; CoV Ue quality of the drugs; (©) the eost of production; (a) the efficiency of the process employed; and (©) whether the product is made from imported intermediates and penultimate products, o¢ from basic raw materials and chemicals. (ii) To study the opzrations of foreign, and/or Indian concerns, who import and pack them ia the country. ‘Phe extent and uerup betwesn the waoly of partly owacd Tndide couderas wit foreign ‘companies. 7 (ii) To recommend steps for encouraging the manufacture of important drugs, which are imported into the country. (iv) To enquire into the scheme of distribution of pharmaccuticat products, whether imported or manufuc- tuted or packed in the country, the profit margin to trade or industry and the part played in this by purely Indian as well as other concerns. () Allancillary matters connected with the above. 6. The above Committee, after a detailed enquiry, made certain recommendations as to how the various as. pect and problems concerning this industry should be examined and handied for its growth in the country. It also observed that the then existing pharmaceutical industry in India when compared with the industry in UK and USA could be considered to be almost noz-existent. It also noted that even after the end of the hostilities, the workd shortage of pharmaceuticals and drugs continued and the tempo of development of the pharmaceutical industry , ‘was maintained in the countty, and export markets for glandular products, alkaloids etc. were also developed. But this happy position did not continue for long. Comretition from the better established and well-kuown pharma- scutical producers, in other countries soon replaced the Indian products from the export markets. Even within the country, the Indian industry fazed severe competition from foreign produots/producers. 7. In spite of the gorwth and progress made so far, the Indian sector still faces competition from the foreign units and the reasons are not far to seck, | I-has been So because ofthe deeply enteached impression created in the minds of the meaical profession by the well-established multi-national manufacturing concerns of their products These multi-national units entered the Indian market with their vast resources with the result, that the Indian sector of the industry now finds it difficult to compete with the former. 8, The Pharmaceutical Enquiry Committee also suggested to make the production of the basic drugs ccono- mical, each manufzcturer of pharmaceuticals should endeavour to produce as many of the basic drugs as practical from intermediates and basic raw materials in quantities sufficient not only to meet his own requirements, but also to dovetail the production programme with the requirements of others in the country. While some of the fins did tend to undertake the manufacture of bulk drugs, they came across several difficulties due to lack of technology, basic chemicals cto. 9. The drugs industry presently comprises of 116 units in the organised sector (units registered/licenced under the tndustries (Development and Regulation) Act, 1951 and more than 2500 unis in the small cals sector.” The organised sector has 25 units with foreign equity exceeding 50% and 26 units with foreign equity of 50% or less. In the small scale sector, 9 units have foreign equity exceeding 50%, while 6 units have 509% or less of foreign equity. 10, According to the Industrial Policy Resolution of 1956, the pharmaceutical industry can be developed both in the public and private sectors. ‘The Government of India set up in 1954 the Hindustan Antibiotics Limited, at Pimpri for the manufacture of antibiotios, and Indian Drugs and Pharmaceuticals Limited in 1961 with two drugs ‘manufacturing units, one at Hyderabad for the production of synthetic drugs and the other at Rishikesh for the pro duction of antibiotics, with the following objectives :-— @ to make the country self-sufficient in drugs and pharmaceuticals; id to free the country from foreign exploitation; and Gii) to provide cheaper medicines in adequate quantity to the people.18 _,, {1+ Out of 116 units borne on the books of the Directorate General of Technical Development (DGTD) 64 units produce bulk drugs and formulations. While 15 manufacturer bulk drugs only, 18 others manufacture only formulations and Shave been recently issued industrial hoences or have beet 1egistered for n*nufucton: of Dulk drags ans formulations. These are 14 units which ace engaged in the production of gelatine cansules, p'.-mt volumes expanders, sutures, ete, with or without other drug formalatjons. 12. The industry has been expanding its manufacturing activity, and the total turnover of this indls'-; in respect of bulk drugs during the year 1973, has been estimated at about Rs, 75 crores, and that of formulations at Rs. 370 crores. : 13, The statement (Aanexure—I) shows the names of the various antibiotics and other major bulk drugs pre~ ‘ently produoed in the country. The statement also shows the production of individual units during the years. 1970 + 1971, 1972 and 1973 along with their licensed capacities, as well as the further capacities which have been approved ‘under the Letters of Intent issued. The targets for the years 1978-79 and 1983-84 estimated by the Task Force set up by the Planning Commission have also been shown in columns 4 and 5 of the statement. This statement, how ‘ever, does not cover the data in respect of small-scale seotor. 14, While the industrial units in the small-scale sector are mostly engaged in the production of formulations, some of the units are also producing bulk drugs, which are either formulated by themselves or offered for sale 10 other formulating units, both in the small-scale and organised sectors including the foreign wnils, ‘The data furnished by the small-scale sector units, in response to a query made by the Ministry of Petroleum & Chemicals, has been compiled in Annexure H. It will be seen therefrom, that a number of bulk drugs like Nicotinic avid/emide, LN,H. Paracetamol, Lignocaine, Phenyl butazone, Diazepam, Diphenbydramine, Diethyt Carbam cizine Citrate, Imi- Pramine, Meprobamate, Tolbutamide etc. are produced by this sector. These drugs are also produced by the orgi- niged sector of the industry. According to thedata available, itis noted that in a number of cases the starting materials Ulilised by the small-scale sector are the same as those used by the organised seotor units while in some other cases, they ditfer. Examples of the first category ic. where both the small-scale sevtor and the organised sector units utilise the same raw materials in the manufacture of the concerned drugs, are as under : Paracetamol eee Diazepam Di-iodo-oxy-Quinoline . - +s Thiacetazone Methanamine mandalate BESS Imipramine hydrochloride Nicotinic acid/amide nese ‘Chlorpromazine Hydrochloride Isonicotinic acid Hydrazide ++ Meprobamate Oxy-phenybutazone Names of the bulk drugs where the small-scale sector use later stage raw materials as compared with those used by the organised sector are :— Diethyl Carbamazine Citrate . . + + . . Sulphamethiazole ‘Sulphadiazine 7 x A . . . . Aspirin Piperazine salts... Tolbutamid? Riboflavine 5-Phos. Sodium 7 . . Phenyl butazone Phenacetin 7 15, The quantum of production ducing 1973 of bulk drugs, which are produced both by the small-scale as well as the organised sector units has beon shown separately in Annexure ITJ. it will be seen that the production of such drugs which are already undertaken in the small-scale sector alongwith the capacities licensed or covered by letters of Intent issued in favour of the organised sector units if utilised fully Would take care of the estimated require ments of such drugs for the Sth Plan period inmany casss. hei 16. The quantities of synthetic drugs and antibiotics produced by'the different sectors of the indusiry.in 1973. are shown below :—‘Wholly Indian owned ua bon Pople Seer Saas wit quite pari rape 30% 7 1 1 ansibioties Penicitin 7 nt 110.65 ‘Streptomsein| r 412 ‘Tetracycline: EEE 7 T 7.08 58.02 Chioramphenicol EE SEE eet t 15.82 31.37 Os re ‘ T 384 i U, Syuthetie Drugs Solphes : T 670.13, 453.81 196,75 Anti TB. . ees T 144.61 315.64 159.08 Anti Dysentery T 33.2 23.70 Aaneleprotic T 107 709 Antidiabetiseinouiin . - MMU : : 8.0 Ssntheties T 38.02 9.08 Anumatarias 7 qe Tv 29.02 oo 20.21 Anistlatals T 1.04 66 Anesthetics 5 : T sits Antiepyretes Analgesics an r 276.48 1387.79 0.87 Anthelmiusies r 66.53 . Barbiterates 7 T 2.18 Cotticosterow hormones 5 eo Kes au 20.68 Phyto-sheinivss : T 595 Bas 013 Vitara a ‘ Mau was Bi ee 7 T Bo? r 7 Be eet Kis. 55.68 123.66 c : v 201.58 Folie Acid Peet 7 Y a2 Nicotinic avid/amide 192 86.18 Vitaruin D3/D3 ‘ 78.99 7 E eee * 3.38 K : 7 7 366.40 7 Paninenoi T - : 0.60 Anichistansinics 5 T 4.35 Ast Diuretics T oe 0.63 Vasodilators eee ‘ T 437 Antidepressants 7 5 T 6.85 4.78 ‘Ant-hypertensive and CVS Deuss T 1.00 ” T Producedfby Immunological agents peeeeee Govt and tadian Others etl 7 t : tis. L736 |20 17. The production of various bulk drugs by the organised sector of .he industry duris 1960, 1965,1990 and 1913 ix indiated ia Anoxute 1V. This shows the extent to which the inlusry has been abl to take up production ofthe bulk drags and the growth attained by it during this period.” Whatever ida Progress may have been achieved by this induetey so Car, i i il far from meeting the requirement othe county. ‘The progress attained so far is not commensurate with the inoteasiag needs of the country particularly in respeot of the bulk drugs. Even for a number of items which are currently produced within the couniry substantial imports are being made. The quantum of imports during the last 3 years in respect of the bulk drugs produced ind genously, is shown in Annexure V. This would give an idea of the extent to which the industry would need to gcar itself to mart the country’s requirements. It would also be seen when compared with Annexure 1, that in respect of a number of items, while capacities have been covered by industrial licences issued, there has been no production the year 1952, 1957, tke approved caper The recog for ck nos mplemtiton vr unde apleen tons popoeermace ihe approved cpedies. The teope fot or indes inplcmentation of proposaoeapectt are many, such as delay in the wremat of equipment/raw materials, poor techoology, management problems, ‘uneconomic production, etc. 18. It has been mentioned earlier that more than 2500 units are there in the sm ill-cale sector. Although authentic data are not available, their production is estimated to be about 20% of the over-all turnover of the indus- zy. Some of these tmallsoale units ars run by wechnologists and they are playing ait important role in the pro- duction cf bulk drugs from basic, stages as well as intermediates and pharmceutical chemaicals required by this industry, Suck units would be abie to play a vital role in the future growth of this industry by taking up the mant- facture of edditional new bulk drugs as well as in expanding the production of the existing items to help mect the future requirements of the country. The pharmaceutical industry provides « wide opportunity to this class of entrepiencurs, particularly in respect of items which involve relatively less capital investment and where teshalogy would pose no serious problem for their manufacture, The small-scale sector could then be expected to make @ major break-through ad contribute substantially to the nation’s efforts towards self-reliance. Annexure Il shows srtum of bulk drugs and pharmaceutical chemicals presently produced in this sector. ‘The Committee during s to the various parts of the country, ated with satisfaction that a number of small-scale units are cone fining their seanufacturing astivities only (0 the manufacture of bulk drugs. without the support of formulations tis necessary to provide adequate incentives and assistance to this sector for its growth, particularly in the field of basic manufacture, U9, tn spite of the considerable growth attained so fr by this industry, ange nambsr of bk drugs sill require to be imported to meet the present demands. Annexure VI shows the namss of the bulk drugs imported into the country during the year 1973-74. . The items have been identified in the statements (a) those whose individual inaport+ were mote than Rs. 10 lakhs ea h and (b) those whose imports’ were valued between Rs. 5 lakis and Rs 10 lakhs. Tewill be seen therefrom that the following 6 antibiotics alone accounted for a total import of about Rs. 5 crores. (Rs. in aks 1 Ampicitin See Se Se 60.69 1 xythrar sabeguenasraensusneee: | 7 66.39 3B Geutamyeia eet eb a eepe eb oe : 7 a 4. Stropiomeia . oo eS aS Sot 69a STeracyeting so 8 6. Chloramphenicol 36.54 Toul 492.58 20, The number of items whose individual imports were valued at more than Rs. 10 laichs, is38, while 26 itet were imported whose individual values ranged between Rs. Sand Rs, 10takhs. To summarise, the following aust of bulk drugs were imported during 1973-74, having individual value range as indicated against each :— eas dove SOW ’ Betwoon Ra 28lakhiaad Ra SOMKeh w Betwoon'Re 1Olakhs aad Re Seed » Betwooa Rs Slats and Rs 19lakhseach 6 Fl . 821 Avrespot of a number of tens where the imports dusing 1973-74 were more than Rs 10 lakhs each expansion. in theit local production has been taken on hand and the imports during the next year are expected to come down substantially with increased local output. The items covered under this category would be Analgin, Tetracycline, Streptomycin, Chloramphenicol, Chloroquin, Sulpha-guanidine, Sulphamethoxypridazine, Vitamin C, and Amp aillin. In respect of rumber of other products. additional capacities ha:e becn approved for their manufact ure Grd with the increased production their imporis would also come down in course of time. Examples under this ‘group are, Procainc. Dilaxonide, Panthenol, Vitamin E, Vitemin P, Metronidazole, Diazepam and Frusemide. fn the case of the following bulk drugs, the projected requirements for the Filth Plan period have been covered by industrial licences and Letters of Intent issued. Kanamycin Chloroquia/satis Sulphaguanidine Analgin Sulphadimidine Indomethacin Sulphadimethoxine Xanthinol Nicotinate Ethambutol Ethionamide Metronidazole Folie acid Diloxanide/Furoate expected that the quantum of imports would come down after the units go into production. 21. Total imports of major bulk drugs during the last 3 years have been summarised as under, group-wise :— (Rs. in Jakks) | Grout deuce I 1972-73.——«W9TRT 1, Antibiotics. aan i ene 416 615.97 ST1.82 2. Anaesthetis/analgesics : ceo 90.65 95.23 113.08 3. Antiamoebic (dyseatery) oe + BG 35.28 40.55 an au 8.47 32.41 1.98 137 702 1 529 6. Anthepiteptics 2.70 5.2 623 7 Anileprosy ; 6 Nu Nit Nit T9864 64.37 . 15.76 2435 18.38 25.64 4.66 10.18 pee ee ee a 4.70 7.54 10.06 5 5 oo oe eee 2.76 23.13 1.7 13, Hormones/Steroids . eee ee 2 86.43, 78.58 98.17 14. Immunologicals ee era ae oar 12.41 12.25 5.98 15, Sulphas 8 2.81 170.77 110.06 16, Tranquitizers : : 1606 14.18 $8.70 7. Vitamins. 5 - 198.87 1848S 246.37 18, Barbiturates : : ‘i aoe 8.31 10.57 7.82 19. X-Ray/Diognostic agents... : 7 fae 2.26 6.49 9.50 Moms eee) os 0.68 Nit 21. Others 40033 310.63 jos. Tora 2109, 1752.44 = 1711.0322 ‘Expocts vs Imports : 22. Drugs and pharmaceutical industry is included in the list of priority industries which carry an export obi. gation. ‘The individual units in this industry ere liable to a cut in their import requirements/entitlements whose export performance is less thar 5% of their production diiring the previous year. Th2 cuts imposed are on a slab system as indicated below :— Export performance Cat imposed 1, No exports or export less than 1% Hebe aeateEC! 20' 2. Export 1% of above, but less than 27% 3, Export 2% or above, but less than 32% 4. Export 5% of above, but lss than 47% 5. Export 4% or above, but ess than 52% eee oe : : 6 Export S%orsbowe 2 7 No cut 23, The above cuts apply to the entitlements for imported raw materials required for the manufacture of ‘the products listed below :— 1, Antibiotics Preparations. 2. Emetine preparations. sulphate. 4. Quinine preparations—others, S. Strychnine preparations. . 6. Brucine preparations. 7. Ayurvedic and Unani Medicines. 8 Antacid and Digestive preparations. 9. Culd, Cough and Bronchial preparations, 10. Asthama, Catarrah and Hay Fever pfeparations, Gripe water. 7 12, Headache, Neuralgia rnd Pain Remedirs. 13, Disinfectants. 14, Salves, Ointments for Burns, Cuts ete. 15. Tonics, Blood Purifiers and Emulsions. 16, Proprietary and Patent Medicines a.0.8. 17. Botanical drugs and derivatives. 18. Beta Ionore. 24. The cut as mentioned above would not apply to the raw matericl requirements in respect of otner end« products of this industry. ‘The export obligation, however, does not apply to :— (® small-scale units; and Gi) other units which have not completed 5 years of production. 25. Depending upon the export performance of the individual units this industry also enjoys a preferential treatment in respect of their imports of raw materials. In order to help production for exports, units which export 10% of more of their production are entitled to the following facilities -— () expansion of their export production; and i) import of their requirements from preferred sources of supply. , Industrial units exporting 25% or more of their production are eligible to import a higher quantum of their requise- ‘ments against free foreign exchange. Normally, DGTD now allows imports of raw. materials etc. in equal portions from ‘both the General Currency Area (GCA) and Rupee Payment Area (RPA), ie the “Actual User Import licence values are divided equally, as 50% from the former and the balance of 50% from the latter. injcase ‘of units exporting more than 10% of their production, the G.C.A. value is increased to 75% and correspondingh¥ \ The -RLP.A. portion is reduoed to 25%, depending upon the availabilty of the required raw materials from the\ Tee ‘Bective sources. In case of esscatist raw materials, additional ad-hoc imports are also allowed in deserving 7 cases. :23 26, According to the statistics compiled by the Basic’ Chemicals, Pharmaceuticals and Cosmetics Export Promotion Council. the exports of drugs, pharmaceuticals and fine chemicals during the last 3 years have been a. Rs. crores 7 7 0.33 ns 37.54 ‘The details of the exports of drugs, pharmaceuticals and fine chemicals during these 3 years. have been gi.cn in ‘Annexure VIL. It will be seen therefrom that a number of products viz, Streptomycin, Chloramphenicol, Oxy- tameptne,Ant-iabetic drug oles than Senin, Chloroguin 4d i ss, some of the culpa drags, Selle ackd, Selicyiamide and mmicals like Emetine, Quinine and its salts, Strychnine and Brucine alkaloids, Ber- berine Hel. ete, along with their preparations have also been exported besides a number of other drugs/formulations. ‘The above figures include the exports of medicinal castor oil during these years as under :— Year (Re,erores) 1971-72 7 7 sear eee eee eo. OB nn... Eo es Eee Ebro eEte CEES EE ata] nm | See ea ee SE tet fai3] 27, Drugs and pharmaceuticals produced in India are now being exported to 80 countrie, including the de- veloped countries like UK, USA, West Germany, USSR, Japan and others, who buy mostly the basic drugs and fine chemicals, Total exports of drugs and pharmaccuticals, excluding medicinal castor oil, accounted for about 3% of the indigenous production. 28. There was a remarkable increase in the export of Quinine salts. Exports in 1973-74 were of the value of Rs, 1.18 crores, as compared to Rs. 0.70 crores during 1972-73, the nuain buyers being West Germany, Hungary, ‘OSSR and Bulgaria, . 29, There has also been a substantial increase in the export of crude drugs, exports having gone upto Rs. 7.10 crores in 1973-74, 15 against Rs. 4.29 crores in 1972-73, Major items :vere Psyllium husk/seeds and ‘Senna leaves and pods. 30, Annexure VIIE would give ths details of exports of drugs, pharmaceuticals and fine chemicals effected during the 6 monthly period April/Sept. 1974, as compared to the corresponding periods in the earlier two years i.e, April—September, 1973 and April—September, 1972. The total exports, including medicinal castor oil, during the half yearly periods of 1974, 1973 and 1972, have been as under :— ApritSeptember, 1974 eee 7 eed « Rs.25.3 crores (stieated) Aptil-Seplember, 1973. : pou 7 Re. 17.66 crores ‘April—September, 1972 7 Rs. 5.07 crores An analysis of exports during this half yearly period of the three years would bring out the following data which would show that there has been a considerable increase in the export of these items over the year -— (Rsflakhs) Tem April, Apa April Sépn.774 —Sept.73 Sept 72 Quinine satwatialoids : PEER SEE 139.47 $8.71 .36 ‘Antibiotics and their preparations other than Siceptonein, Pnicilin, Oxyletrayctine and 2113.50 988 GRioraraphenicol Or ee ee Nux Vomica alkaloids || wae 37 6a ‘Certain suipha drags : SEE : LR 0230.02 Salioic Acid. : Fett ee : oeee wor 060.08 Modiinal Castrol | eee 1563.89 1229.08 37.68 Salkyamide EEE eee ec 43 i i 31. Besides the geoeral export obligation under the Trade Control Policy, certain specific export. conditions aco bing imped now wile apron pops tinder tae Industnes (Devel it ‘& Regulation) Act a particularly for the fof new drugs as for expansion, "in the case of firms hay foreign oquit ition. . The wa HT export sipuistiog ibpered wiles berween 10% aad 80° Nebeading onan Tre oF ine product as ie posible demand sa the export marta 1M of Pet. & ChemJ75—A24 32. The data furnished below would show the growing imbalance between import requirements of the industry and the export earnings : (Rar) ‘rgpouts of drugs, pharmaceusicais and fine chemicals 1963-64 2.00 196566 | 4a 6 7 1967-88 | 4.63 |} incl. Med. castor oil 1965-70 | 731 50 197 10°33 5 tne | 374 eae Import of drugs and pharmaceuticals ete. (Raterores) 13664 vee ee Te en eee eee ee ee ee 1965-66 | eee meer een eed + 3.90 1967-68 oer ee er eee 26.51 BOM. 2. fol 26.19 wm, Fo 35.04 to 30 pam. 2 Lt a4 Jt may be seen that while exports have gone up from Rs. 2.00 crores in 1963.64 to Rs. 37.54 (Rs. 16.41 crores, excluding medicinal castor oil) in 1973-74, imports have gone up from Rs. 13.17 crores in 1963-64 to Rs. 37.50 crores in 1973-74, The production of finished formulations during this period increased froma Rs. 120.0 crores in 1963 to Re. 370 crores in 1973. This would indicate that the industry has to strive hard to reduce the import bi through increased production. 33. Distribution pattern of drags It would be interesting to ceview the shares of the various drugs. according to the different therapeutic, groups, in their sales through the trade channel, A study of the market survey undertaken by a commercial re- Search group would reveal the following interesting data. The study made by this research group is based on the sales of finished medicinal preparations of about 120 companies effected through the trade channel. These data ‘were worked out on purchase records maintained by 532 chemists spread out all over India. These, however, do not cover the off-take by the non-chemists ie. the doctors, hospitals, Government agencies etc. The following percentages against the various categories of products during the years 1969, 1971 and 1973 have been worked out 1. Antibiotics 2. Vitamins a 3. Cough & Cold preparations ‘4. Haernatinics : 5. Tonics & Health restorers |). 6. Hormones ner 1. Defmatological preparations 5 a : ' B Analesics 5 9. Antistheumatics are ‘ 1. Antiiaethocals ao 5 MM, Dietetics. : 12. Enzymes and digestanis 13, Cardio-ascular drugs 14, Anti-spasmodics 15. Psyohotherapeutics 16. Opthalmologicals eee eee eee ee AT Aniasthmatiog WAmocbicides 19. Anti-T-B. preparations : aod aoe25 134. As mentioned earlier, in the computation of the above figures, only the sales effected through the retail trade channel have been taken into account. Significant purchases are also made by the Government agencies, * hospitals and doctors, which have not been reflected in those estimates. The iow percentage in respect of Sulpho- nomides and AnticT.B. preparations could be due to the fect that such preparations are made available in lenge quantities 10 the consumers through the hospitals and other Governinental agencies. 35. It would be seen from the above that about 22% of the market share is enjoyed by Vitamins, Tonics and health restorers and hacmatinics, while about 20% was shared by the antibiotics. There has been a decline in the sales of Sulphias through the trade and an increase in the amoebicidals. In the case of other categories of medicines, the market share has been rvce ut less the same over the years, witit uur changes. Research and Development 36. It is well-known that the drugs and pharmaceutical industry is highly research-oriented and the key role that R&D plays in this industry cannot be over-emphasized. The need for intensive research and development work in any field of industrial activity is of utmost importance, but this is more so in the field of drugs and phar _ maceuticals, 37. According to the present estimate, the expenditure on research and development activity incurred by the industry in India, is about Rs. 4.5 crores per annum, about 1.1% of the total turnover by the industry in 1973. ‘The expenditure is woefully inadequate when looked at from the angle of total turnover by this industry, vis-a-vis the expenditure incurred on R&D in the developed countries and the turnover attained. While the expenditure by any individual unit hore does not exceed 5% of its turnover, except for Haffkines (14%), the R&D expenses in- ‘curred by a number of units in the developed countries range between 12—15% of their turnover. Although some of the foreign units operating here enjoy the benefits of research undertaken by their parent organisations or a330- ciated laboratories abroad, it is absolutely essential that these units also take up R&D activity in right earnest. 38. An analysis of the data from 71 pharmaceutical companies in the organised sector revealed that while 54 companies have research and development departments, the remaining 17 companies have made no investments 50 far in research and development programme.ANNEXUREL Statement shoxing sames of major drags Unclding Antibiotics, Capacities licenced, Preduction targets etc (Chapter It—Para 13) tom Unit Target af require Name wns ieeer Total No. oe tore of of 1978599 1503-98 Koon, oI totem 7812 oie acl o @ o © © © o ®8 9 @ a cH ay Antois 1, Peaiiin MMU mo 1860 EDP. $4.21 56.28 tat. tt 5e t0.6s - Alec as ot Standard a33 4s 9 2: Streptomycin t ms 1650 108 ses 3. Qhlorampheoical& its T 390780 Parke Davis 2 Nt 9.51 970 1.9 es Breage Koot! 39 2has 43h akg Ia. Des SS tna “acer Na 1538 Mite taba. og [029 049 2. oar Thoms § New Uait 37.91 47.06 41.06 47.19 133.0 4. Tetacpetiog Hel, 2030 LDP. 7a IL 482 tse actades Ghorcra- i Nit Nn Ra NL greiae & Dima Srabltics ots St agony Glortetacyetine “Gyananid ar Ses 70 Re Pizor ant TNS 5. Onvtewneyetioeg 88160 Phase 25.35 29.46 36.59 39.72 Dee. 605 1195 *S:08 10.8 6. Dimethyl-Chlortetracye- T Be) 46 Cyanamid 6.82 4.62 7.71 8.78 ' 7. Chlortetacyeting + LDP Nu Na Gjanamia as oles ones *Veteinary Quality Bao v7 18.8 8. Amphotericin =. T 36 Syabiotin 1 186 025 0.85 0.29 1 9. Neomyeia Sulphate. T 1015 ‘Syabioves = 0.30.82 0.87 0.66 0.34 Hal zo OM ON SN st 5.00 To. Nystatin... 30 4.8 LDPL. 10 0.62 0.74 0.27 10 26opti & other 1 Se aote Pniiine 12, Bacitacia wu 13, Cyeloserine Lt 4. Enthromycin Base & " Esters 15, Grscofulvin t 16, Hamyeia Kes. 17, Kasarycin r , Olsandornycia Kes 19. Doxyeseline 20. Polymmin 5. Kes |. Cephalorioe 22, Gentamycin 2. Rifampin 24, Framycetin 25. Lincomyeta 26. Aureofungin Sulpha Drugs. 1, Sulphadiazine . 0. 2. Sulphacetamide & doris T 3. Phthalyl Sulphathiazole T + 4. Suosinyl Sulphathiazole 5. Suipisamerazine T a o Ss 10 Pubaey 5 Ciola a75 HAL, 3 Aiembic 5 Uniciem Noa pacity fiked a 46 8 16 3069 Alombi 6 ‘Themis 4 Wat. Abbott 20 40 LDPL. ‘6 190 0 HAL, 250 0.8 1.6 Alembic ' 130 2400 Randa EDP. bo 260) HAL. os 250 460 Atul 139 May & Baker Cibatal 30 10 LPL, 50 eist India is tional Immunity Albert David 150280 M.D. 3s LDL. Cita May 4 Baker 819) Mad Baker Merck Sharp & Dohme 3S Mas oa MH 4 C3) 15.75 0.2 0.16 1.08 2.88 6 fo o0 6 15.21 oil nil al 20 1 25 501s Nu NUON Nt Nu 0.77 4.33 289 S835 33.95 5108 “D.a7 435° 30.09 35.73 S474 59,72 94.45 19.35 32.22 0.8 2 10.75 142 570 Nil ‘0:08 "Nt Nil Ni Nit Foto 4370 689 109 0 Nil Nil Nit = f= Nil Ni Ni NN6, SulpnathiazoteSodium T 1. Sulphafurazole tv 6 8. Sulphamethizole T 2 9, Sulphasomidine/Sodium T 260 ‘tinctediag Sulpharioxole) 10, Sulphaphenazole/Sodium T 180 11, Sulphamoxole 1 4s 12, Suiphaguaniding =. T as 13. Sulphamethoxy- T “0 Poridaaine 14, Sulphadimethosing 30 15. Sulphamethaxozole | — - 16. Sulphanitamide T 17. Sulphadividine) t 1010 1, Sulphapyridine r 19, Sulphacetamide T ‘Phas Cibatut Suiphadizine Sulphathiazote Sulphasomidine Sulphaphenazole Salpharethazine Anti T. Drugs 1. Pas & its Sales. May & Baker ‘Atul Peodueis, 240 (2) ® © a aD an, Nil NNN UT 687 og.es 19 37 188 $5.07 1013 156.59 = 36 199.30 118.24 i818 317. 11824 1D LDP. s 465 Ciba sun Sioatt $68 ‘German Rome: ios 26" Ni wn 350 Gata ois 4649 3.72 14.28 Cite Sent $455 toa 9a) EDL. ie een ero 70 Gepvan Rene. ‘is 27 10.91 15.52 34.02 M5 LDPL, 230,186.54 210.40 208.64 268.97 » ss Lor. 0 — Roche i ia a5 tot. ror. 150 846 13690 13169 71.8150 2000 EDL. 50 126.37 223.79 218.86 328.81 S00 May & Baker at 0.12 an “0.08 cat it Oat ni May & Baker 4s ad nao ast ta 035 9.07 nt il ‘Albert Did Te SS os 1s at at al 8.03 0:35 TDP. ws SOS tat (Combined Capes for Sulpha Drugs) ost not Silphanhenazte Sulphadiseae Suphasomiine sug Suiphathigste Sulpha met Mhenazte sulpstmerazne ets mei Sulphapyeidine Suiphathizte 1200, Haryana Chemials — «0 ANE Rah = cy ir. il 36.25 98.69 135.90 250 Pha HO 9536 8454, 98.96 li9'33 Bio Bane 10 320 19's 70.10 ‘S6'a6 Blo syath 100 35: 10440 Wander 500 182:96 150.84o 2 1. Heoniazid (UND 3. Thiacetazone 4. Bthambutot 5 Pyrazinamide 6 Morphazinamide 7. Ethionamide Prothionamide Ant Desentry. Deves: 1 Halogenated Oxyquino- Todochloro— Hydoxyquinolines 2 Dilodo Hydoxyquino- lines (Capacites shown against ‘each unit cover both Die fodo and ‘iod0-Oxy- unotines) 3. Di-Brome Hydonyqui ‘oline a a4 o 122 n 450 140 as o o @ © aa «ay a» ‘Cal Chemica - 0.05 ail Ranga lmmacis: 2824.98 Chemo Pharma 38918 20.65, os Gils to on 17 Bio Evane 9.96 9:95 12164 Symbiotics 2 340 13198 ippt, 20 nll, al B.CPW. Me ets ane Pires so onil 16.62 Suneeta o - ne Alber Davia = = a Water Hindeyan 50 all Dev Corpora of Konkan 100 438.56 Bengal Immunity Bio Evans Chemo Pharma ‘Unichem Albert David Sunecta TRL 27.6 ‘Themis LDP. 1s Gyanamid Sarabhai 1 Suineeta 2 PLC. Sharma 5 os Uni Sankyo 3 3 Sunceia 2 Themis = 2 Themis 202 East India = 230.85 338.42 38.24 25.77 Atal 8029.49 42.0.1 30.65 38.88 BCP, © 035 64S 0.30 0.29 Albert David 0.13) Nl ON 0.38 Simbios 7234216 0.73 OL Hind Chemicals 7,2 Ri 0113 0:02.15 Unichem 35 30s 8.68 2.27 78.17 73.02 72.79 Albert Davia 2.39 East India 0186 0119 May& Baker 4.200 4.32 1'57 Synbioties 394 0.29 Bio Evans 29 272 BCP. 0:03 0.08 BI 17 O24 Therapeutic 120 = 440 IRek 8 = 0:20 30.6 1297 138 42.77 17.40 393.6 Sandoz BS 1435 14.63 117 10.26 1230 oe a 8 ae ae Renee es S timine Deas Kas 98) HO Regge We 2016 1.204 16. 23.8 = a a a 8 ie Gemnisuck Tape Qa Om Sa eR Te Oats oe foe . as, i ae if PR nosey % nao Pier emer ee eo ae cee 2 ue . Cipla 25° 3S Perea ee 1. Dasizodipnngt Sa T 30 aw, tne Pocweetena se peewee fees Rc ee Es = oa a goheiine fate teria... MU 3000 con ou 00 vs | 2. Tosanide 7 3 1 entre 18 e om md hetomeguite =. TO aa oe Coe Nil Nil i : eee, Aunts rr Se aA $: Banta nod Ant Ms inne Sats om, Factor NS al Madras % = U9 11.69 12.73 87h om BY US BR Su om = UH SE SH BH a tiaquin T ss 116 Parke Davis 3624.06 16.98 25.74 9.89 ‘ ciereen Albert David: 1 ‘Nil Nil 0.05 Nil i eee : cane A. cuorogin 2s Sate TO Sue a Be ne m2 em ee ate Suton FR PP BP OB au 8 ihe iors . 5 fa & 15.79 "22.70 24.58 15.20 4.Pdmaquin 2. T 1s 25“Go “a i 1 Diahfewtam sare Ta ~* Bite 1 maestheties: 1, Procaine HCL. tT 20 2. Xylocaine/Lignocaine T 4 A. Biher BPAnsestheric. T $10 ABtiylCworide =, T 150 5. Halothane 6. Carbocaine 7. Marcaine 8. Ketamive Hei. Analgesics, Aniipsreties & Anni Gu, Laspitin 5 4. T1900 2. Sodiurs Salicylate. T 600 3.Phenacetin, =. T 500 4. Paracetamol =. 0. T 400, 1M of Pet. & ChemJ75—5 os 880 250 3500 800 om Rurcoughs Well OP, 0 Cai ee a Hoechst Hico Products tre. ‘Ammar G. ‘Aziz. - ‘Suh Geigy Unicher 2 Alembic 35 Hyd. Chemicals REP 1 Andi Sugars — ‘Alia 60 Martin & Harcis 300 100 Alia Labs, 420 {indosat 0 Calcutta Chem cals Nia Products GM. Swamy LDPL, 350 East india s0 Cateuttn Chem wale Has 696.09 5.88 19.02 o 755.10 37 8.76, 26. 29.95 Uo ih a ae, Nil 0.08 oS 3 as - - © 788.68 744.90 Tah36 76.92 22 Nil 2480in a o @ 1 an. an 5 , Atta 120 15.00 16.00 26.00 21.99 Albert David 2:20 r ‘Alia Labs, €00—-497,90 1019.98 1615.24 1324.32 219100 227:00 IP Grade Iedosal $2.64 39,53 Ni NT Caeatta wgeemeas ONS NT NN na. See - - = 6 oMsmmy SS = 2 6% 7. Methy! Salicylate Ata 250 87.85 103,98 155.89 195,00 Cateut ‘Chemicals — Nil Nil Na GM. Swamy 0 8. Anatgin T 4 800 LPL. 4606.87 67.8 77.63 136.72 240 9. Amidonprine T LDL. 585K 10, Pethidine Kws, 1200 2400 Gluconate 750 e216 MO 30 11, Phayibutarone =. 200300 Themis 30 sim so Suhrid Geigy 39218 11.07 indo Pharma 4 Pic Sharma 25 12, Ovyphenyl Butszone 50 100 Suhtid Geigy 12 3.59 7.23 1X, tandomethacin T 1238 Themis 8 LDP. 3 14, Protenesi Kes, 12 2100 Suneeta ¥2000 15, Allopurionat T DPI. 2 16, Dewteopropowyphene .T Uni Chem 6 +, Tei itorophos Sostium —T. Abbott 18, Ibuprofen 7 Boots € Gipla Se Peet eb pe tuttelnentics 1, Pingravine &itsssles, 7 ns 200 LDP. 50 21.90 28.58 43.73 66.53 65 2. Bephanium Hydoxy- Nanthoate T 1s 30 BW. 5 3. Treibendazole 4, Niclosamide 5S. Tetramizols 6 Pyrantal Pamoate/ fartarte 7. Mesulphen t bayer \ O12 14s ont nit Rorbiturates 1. Phenobarbitone T M0 EDL, 153.76 8.97 9.76 9.18 1S 2. Anylobarbitone TF 20 3. Secobarbitone 0. T 0-2 EPL Ma 4. Dialiybarbitone T LDL. 7 5. Thiopentone T as Anti-Depressamts 1, Imipramine eee eeeo ” o oo 6) 4 ay 6% ay 2, Amleryprnin, SOO thers 2002 23. Methaquatene 1 ow 4. Chlordiarcyoside © 2 Ranhasy Rocke oy 5. Diazepam r os 1 hppa 1 iia oF 3 Kasbany 4.00 Roche : : “ 6 Chlorpromazine 12 May& Raker 2.5 Lan 27 2s 7 Phenothearines & its tah 2 4 May&Baker 0.5 129205. 0s 8 Meprobamate . 0. 50 Sunceta 30 136 23.75 Geotfey Manners Le 1a 23 ahs 9. Haloperidot 10, Dexebin 11. Thiothinene 412. Sintamit Kes iva 3100 13, Nitrazepam Kes cipla 250 250 18, Trifvoperacine Hel. Antettypertensices and CVE drugs 1, MethylDona 0. 50100. Sunceta iopt. Themis s 2. Guamthidine Kes, 3510 Ciba 221188 oil it 22 3. Prenylamine Lactale. Kes. 16003200, Hoechst, 00 $00 4. tsoxopurine §—.. Kgs. 10602000 Dupher so $00 S.C. T 2 4 Themis 2 Ranbaxy a Cipla 1 Big Evans 4 wom Kec 6 Mephentermins . Kes, 200400 7. Propanaint . 100 8. Salburamol. Kegs. Giaw , roa 9. Practolol Gola ‘ 1 ‘ emis $6 Arki-Histamives 1. Pheniramine r 65 13 Hoechst 1922.06 3.87 3.48 2. Chlorpheniramine 1632. UniSankyo 2 Indo Pharma 4 3. Dipheniydramine | T 1632 Unichem 3 982 248 0.86 Parke Davis 628 Teo 0s ° 4. Meppramine Maleate . May & Baker - = on 2 Viveins 1, Vitamin A MMU 50150 Roche 1s 19,88 23,52 27.81 26.79 As Giaxo 3017.09 18.66 21.72 20.59 co 3697 A218 9.53 47.38 iy tic. H hrate T fo 200 Lor. 1 @ 5.9 15.4 19.47 27.39 1206 o ® © a Gb «ay ay : LDL as 228 68D ay ® r 94m) LPL $0 Freris By Surabhai Ro 2 (Come Htrasy Ba wm 6 MS Eff 98.70 115.13 142.37 123.60 Theos 50 2998 890 So1ky 42 as Membic bo “6k 917 tos “RT Glaxo’ 6 o's) ail omit nit Synbioties 13.2 S15 535 8.03 233.2 140.84 198.55 218.29 178.68, 233.2 6. bolic Acid r sae) 3S 0.40 Lot 4.57 242 7 Panthenol& 0. %@ 9s 500 Ot 0.00 Pantotherates wo 45 5, Vitamin C& Salts. 900 1800 129 194.6 241,87 254,56 261.58 Tas PLS MLR sen Suineeta 25 ge ee) Re. Gandhi 150 370 194.05 241,87 254,56 261.58 520 9. Vitamin DE DS Keys, 109) 2009 Dupher 1099 91.87 71.07 141.4 75.99 1000 10, Vitamin t 9 18 Rooke = So 88 E. Merck: 3 U1 Vitamin 5. Kgs. 18-2280 Atul Products 450,386 AZ 4366.08 Glaxo 12. Vitamin v 5 6 nil ail nil 4 4 13, Nivotinis Next r 19 1200 Chemo Pharma «6519.81 IND 6.453 1 Ginia 12 "639 22:73 3186 Ssnbioties 6.16 nit “nil Bice. 12 020° ail LPC is - 0.68 “Therapeutic ees Chemo Pharma 9.2 6.67 5.76 Cinla $06 6.90 5.2 Senbioties ital nil Bepw ‘ay 0.03.01 LDPL. 2 0.3) 126 8156 800 irc nit "ail O15 . Bio Evan 2 5 WarnerHindys- tan 25 41.23 49.48 29.84 Sunceta, a 1634 16.75 30.55, Fast India o Fi . : He. Shah 100 Dor, Carpa. of ‘Rookan 600 Dineetee Uydrochtorthiggite 880 Ean! Inga 0.5 ; Ciba 2 6.36 63 O60 6.58 MSD. 3 G36 0.02 0.03 0.05 2 Myltomlumetiingwte 7 wo (Includes Chlorthiaside also 3. Polythiazdie r 6 3 4. Frasemide v BST 12 0.173 5, wo 2 5, Acetazolamide .. 2s 2s 6 Spiranolastone .. Ks ~ 36.55 41.07 7. Bendrofluazidea GH w m 8) A an ay 43) Anirpara bein 1. Lows . : ; 2, amantadine Vasobiauors redrine ’ sw sed 0.21" 0.09 4.45 4.37 rion nit nd Mitt P| O29 0.02 hil “Theophislline/ Amino 2 iste - 621M Khandehal aa coe 3, Xanthinol Nicotinate | 6 12 German Remedies 12 Se 682 inks 3 Hormones & Steril: 1. Ethisterone Kgs 4x0 1002 Wyeth 2s 170 wt nit 2 Kes. mano 3, Progestrone & Salt Kus W240 Ci wr 6 3s a Epi B0S.08 27/3062 02 Ween S208 1740 246.50 4 Norgestrot Kes S10 5. Mesteenol/Ethinyl Ese tadiol Kes 2 6 Ste bor 0.66 2.35 0.20 6.62 0.67 0.67 6. Testosterone Exiers Kgs 6801409 Ciba 30.80 24.30 1289 18.68 Weeah PANT WDSSN A085. ¥6807 Che S30 175.09 4.36 4837 Searls so an 780 it 7. Methyl Testosterone wr 400 1549s 8. Lynesteanol 930 Pd Sk STAN HE at oe Corton Steroide 1. Cottisone . Kas 670013009 Glaze 5.29 8.66 Wel Tas Rus.D. aie Onl 2 Hydrocortisone. +4500 9000 Gla W236 SB AS 2.08 Wweeth il) 737.350 29458 ASR. MED, nit aie) ait nit 3. Prednisone | 109 Way kes 39 3.0 R aint S138 S838 89S 10.75 4. Prednisolene 1500300) Glaxo nil nil nit it Wyeth ni il $94.97 $36.90 MSD. nih nail nih 5. Triameinbone/Aceta- nde’ : 189 6. Dexamothasone Ss 150309 MS.D, TS 194 3.94 18,25 7. Betamethasone Kes we Glo 6435 78.26 93.00 133.80 Others 1. Adrenaline Salts. Kgs 96 199 Burroughs Wellcome 4 30,08 37.61 15.00 sto. 971. Ast. mR) By 2. Nor Adrenaline. Kev. PR 2 3. Oxytocin. MU 0450 4, Isoprenatine36 Bengal Immunity 283.44 437,99 1 2 3 eos 6 7 8 9 bb wD 2 © Dogs of Vegetable Origin 3 Acopine Homatrapine Kus 75120. Meta Phas Oa7 Nil ONL Ni 3. Hyescines : co ui i 4 Hyosyamine J 5. Buty! Hyoscine Hydro: ‘eremide Kes % 10 6. Digoxin Kes 150240. Sandoz. Nil NBs Baw. B28 9D 82 4.60. Hind oo NNN 7, Erogotamiine 73 120 8. Caffeine & Salis T 1 350 BEP.W. © 15.78 10.59 18.41 22.30 Mehta Pharma 0.07 0.016 0.03. “Nil Smith Stani= street $1.25 105 0.10 0.30 Hind Chemicals ‘Ni, 9. Morphine & Salts. T 1600 3200. Govt. Factory 1,00 0.56 0.75 0.66 ‘Ghazipar 10. Conleine & Salts r 2 40 Govt. Factory $933.25 725 57 Ghazipur 11. Narcotine & Salts 32. Papawerines r 6 on 13. Resernine Kes, 2040 Mehta Pharma Nil Nil Nit 14, Strychnine & Brucine 7 60100. Smith Stanin- 1S 4Se LBS 6S LTS Mehia 9.20 8.54 ISL 13.63 Bio Evans Ta2 Olas 14168 "4.02 Rew. wT Nn ON 15. Quinidine Suiphace 7 1530. Cipla 0.25 0,28 0,16 0.15 Govt. Factory Fall Nad) 0.13 0.05 0,07 0,12 West Bengal Sera & Vaccines 1, Tetague Antitoxin§ MU 30000 60000 Bengal maturity 3046.2 4455.4 9223.2 6201.53 Bio Evans 31% “487 889.10 4686.00 Deys Ses Ra SON" NID the ata iares ucpw. BOLO) soli 97.43 187164 pect ot Bio- Haikine $80.98 06K 1876.20 1687/00 Tagical ‘product ‘ Chowgale = Ni Nite are. natcon. plete. 6791.63 10080.5t 16090.91 12745.17 2. Diptheria AT mu Bengal Immunity 584.61 497,22 562.69 438.08 Halixine 68.55 149" 331.44 355-00 Bio Evans (Foxoid) Kes. 302 200 340 bepw, 0.80 Nil 0.20 617.16 989.02 3, D.T.P.CTriple Vavcine) M Dows 200 4, BCG. Vaccine _ 6 130 5. Polio Vaceine 2040 Lit Lit Lit 6, Tetanus Toroid 3270 Bio Evans. 34635853 GAGS 5145.00 BCPW, i928 12.97 13.92 17.39 Glaxo 223) 10nt Nit = 1487.002, Dinhther'a Toxins 8. Gas Gangiene AnteEplepres Phenyl Hydantsoin & Sinan 7 n 7 4 1.64 1.50 1.48 um Gluconate bert David 4 4 tee eet a eres WNL-81 120.63 112.66 14:92, 17.50 ‘19.30, Ni” Oh ONL 150 440 60.70 73.40 ieropharms S38 “Oo tas Nile Products NON 7" 2. Ferrous Gluconate T 12000 240 Bar rm 2.06 0.34 4.19 Nie Broducts Ts Ro 2B Sandoz 0 ates 150 ‘ber David Nil ON 028 4. FerrousSucerate, . 1s 9 4. Fereous Fumarate. 7 50100 Rallis 12 Sandoz Fy Gnlchem 2 Chemo Pama NA, 5 FerrousSulphate 2080 6 Nikethamide & Salts. T 25 0 Cast India 13s 0.02 NN Berw 0:26 905 O12 ONE Atul Products Ss Sos 279 fas Standard "Nn “St Cie 7. Furanotiding 0. 30 @ Indo.Pharma 4 ire. 3 Power Cable B Nivofurantoin 7 4590 Indo Pharma 4 iret 3 SKE LPL. Sarath Day-se-Chem Power Cables 9. Nitrofurazone t Indo Pharma 4 i rr 10, Natigicte Acid = Ranby Pa Menezes M1, Azothioptine - - 12, tron Chaline Citrate - - 13. Trimethoprin ~~ aw 36 Cin q PL. 14, Sod. Cromogtysate 7 = = Coola Am-Micotes 1, Methotenate . . Kes, 200400 2 Cyetophesphamide . Ken 200400 3. Hydroxy Urea 4. 6-Mercaptopurine 4 Testolacione 6. Thiotepa 7, Musitee Het3 Beat ] ‘Sodium Meglumine ee eee sagan | on Dome . cae eer: a ae eee es ea SooANNENURE (Chapier Hato 1. Done peakistion 12 the Sinai FS. Name oF the bulk drug Nave af ms wpe iene tneers : GER ay, isi ar Ea arene - Chemipharin 2: Frichein Laboratories ik t 2: Chemin Masherat Chemicals patenks : 5 é 1. Paracetamol 2. Diethyl Charbarnvine Gira . Dilodohydroxyauinotine Tnedseies 1 Warks js Dangarsey ae Co. armegeical Ft Piperazine and its Salts rich faboratovics utah. Doar 4 C9. 1M 1 “te Chantoc Sochcmt Nivea Chemicals Pett 5. Vitamin 8 2 Phosphate Sadia 6, Phenao-tin Nivedita Chomigals Po Li Trichsm Fataveries Rit Pharmceutical Us Pletsmsssnth Chane Sachem aboratories set, Td 1. Calcium Lactate Chemipharm ‘Crystal Chemicals Chlurnheniramtine Maleate 9. Dinhenhsdramine Hoteochloride Chemiphrm heoiptienn 1 1 4 6. Acow Ch 1 1 1 10, Menadione t 1 1, Methaguatone Chomiphaen F2. Mertranoaine Mandate L Chemioharns Pisrnegeath Comic 7 13, Sulphertiarine vinharin Trichem taboratories 14, Sunciny! Sulphuhiazote <1. Chemipharm 1S. Papin 1, trae Poa Comoration Hare chem, bakes Pate Lt 39 M of Pet. & Chem./75—6 Poadacios m0 Kg. ay-78 Be Kes. 975-79 18 Kee 714 30 Kes. 805 Kes 21000 Kes. 200 Kes. 40000 Rex. 97-7 ora tas} e200 Re 100K. mn M55 Er ‘000 Ke 1297 fas (or 1973) a9emzn 978.75) uonen ae areca MO Kes MOS Kes SI Res 750 Kes 7 Re 198 Kes 06° nts15, Niewa Act amie Perberine Hel Ovyphendurazone 8 Diazepym FI Sulphameshizcte 24, Ferrous Fumerate 25. Aspiin 26, Magnesium Trsilcate LP, 27, Imipramine Hydrochloride 28. Thiacetazone 29 Pheayt Butazone 30. Chlorpromazine Hel. , 31, Salieylamide . 52, Dried Aluminium Hydroxite Gel 22, Glyero Phospate(Sodiam, Pots. 34, Meprobamate 33. Tolbutamide 36, Calfeine 7 37, Todo Chioraphydtoxyquin emmeay er Lid ats & Chemicals British Pharmacenticn! Tabs etka Chem. tai omplant Industries Inter Chern, 5: Pharmasyath Chemicals Parma indiana Laboravories ‘Sucker Labor Strom tn adustiat Chemals Li. Biochem Agencies |. Trichem Laboratories ‘Unique Pharmaceutal Labs. 5: British Pharmaceutical Works : Pharmasynth Chenscals 3 4 4 Eagle Pharmaceuta! Works z G. Dungarsey & Co. Pvt. td. 3 Phumasyath Choneas £ Bio Chem 6 5 t t §. Dr, Karaivhs Pharma Chemical Industry Svarho. Katha & Aled Industries Pvt. Lid 1. Mulrai G. Dungarsey and Co. Pt. Lid Unique Pharmaceutical Labs. British Pharraceuticat Labs. J. Nison Laboratories 1. ison Laboratories 1. Unkversut Chemicals 2 basi Che. 1. Gujarat Chemicat_ Industries Hansa Cremicals Inver Chem Pharmasynih Chemicals Basics Industries |- Pharmasynth Chemicals Syntho Chem t 1 1. Pharmasyath Chemicals 1, Pharmasynth Chemicals 1 2 1 ‘Sovin Chemicals Tad Atvatice Li, |. Unsar Pharmaceuticals 1. Basichem Industries Dr. Karanths Phat Associated Drag Co. P 1 1 1, Sunny Todsties Pot. Lik 2, Noogy Laboratories, Lal 2 7 Kgs, 1973) & ob 1600 Kgs. 88t0 REE Be 1020 Kes 750 KE 1732.5 Ki NAL 13.5 Kgs. 85 Kes. 2 Kes 2D ke 51200 Kes. 385 Kes. 310 Kgs. 25400 Kes. 271 Kes. 6780 Kes. (1973) amy 4973) 4973) ag73), 973-74) 973), ag72-73) 1973-74) ess 9078.4 az agp. dsr cag73 tag73) 1972 A973) 97) 973) ag. 972) as) ch 1978) 1973), 1978-78) a9.79) 4973) 973) 83-74) 1973) a7 a7) asm) (973) 973.78) (1973-74) cag7yy as737) a9-74ANNEXUREIIT Parlier ot sae Irla Monga the Ocgunived aud Sov tieorle Seesare oasis Fit Phos Dace Vols Total Total Casaciey int rxlue-proviue indige-— gipned tian rem Uni: Timi Homie game” inthe canes simalle the orva- roduc: et Scale niedlser~ "tion PEPE s 6 ss Paracetamol. chee iHet 102.28 18.62 120.90 4400 2, Dec : 7 eEoe 3487.65 S56 4s 3. Halogenated S-hyuroxygsinoline, 4594 1005 M6 437 a8 HOF 66.88 80.57 ISS T T T A Piperazine Bsa r 5. Vita win BE IEEE T0888 La ta t6 T T T r 6, Phenacetin 4067 IMSS 177.82 >. Niitatinie Ackdamite eb DAR 101.49 1O.AS 8. INHMfsoniazi 17.95 96.48 UN 9. Oxypheabutazone 0407728 7.689 0 or Pashaly! Sutptathiacac . ee 1, Diazepam 6 ec 12, Ferrous Fumerato 5 r 13.95 wos RM 13, Aspicin : Eee r NA SRE ams wy 14, Pens! Berazoae kas t 15, Thiasetarone F 16. Salicylamise ' 17, PAS Bitssals T NAL 4827 498.27 4 1 v.s10 $7.67 S798 yoo He 449 0% 6s 20 18, Tolbutaminle alANUSLNURY 1V ett 0008 BABS niga dart 9S, 1983, 1960. 1965, 1970 & 1973 (Chapier #1 Para 17) st heer Unit 192 198719601965 IVD 1973 No. 1 3 5 6 1 8 9 1 Amtibioties ¢ 1. Penisitin 7 : 17.5 39.7% 1031 247 2. Streptomycin 100.7158 179, 3. Tetracyclin 192m 2s 9. 4. Chloramphenicol 15 3819 29.3838 a 5. Amphotericin 7 1 5. Erythromycin 2 RG 1. Nooycia Saphate mato Hh Anti Bysennry Drugs 1. Halogenated Osygainotines : r 4a! 2019 21.619 70.07 90100 UML, Anti Diabstic Drugs: 1. Tolbatamide 16.76 at sn 2. Chtorpropaniive 19 6 9. 3. tasulia 37S B07 8 1. AntisLeprony Begs ¢ 7 1, DDS and its derivaties r Oss 2 7. ss «6 V. Anti Puretics & Anagesies 1. Acetyl Sacglc Acid 76.312 413.40 mn, > Pasnacetin 15.558 3.52 16 3. Paracetamol : 1. 4 Anatgin * . : 136, 5. So4.Salicyeate 3.12 11805 319.46 NA oa, ¥ pathitine Hl Fi IN 20 Vi att TB. Dewees tin : SHEE os 14.82 29.087 56.2 2996 2, PAS Aits Sats, r + ALSY 82.988 338.90 658) 3. Thiacetazone et : : 7 rr Vil. Aneesttes : 1. Procaine Hel eee : 17 om 2 Xylosaine/Lignosaine + r 0.48 1.72 WIL, Syutesi Hormones: « Kes 1658137 1X. Anti Metariay: oT + 0.06 Bo 1. Chloroqui &-Amodiquin X. Alkdoide& Allied Drugs: 1 Carteine : : r 2.790 5.28 12.668 15.23 17.1 2 Emeline He, | ro 2 Kes 26s 3. Gphedrine : see + Kee te a er) 4. Quini Tr a 9.291 47,79 49,025, Strgehnine & Brus t 8.3 6 Reserpine a XE. Sulpha Dregs 1. Sulphadiazine T eee) rT. cee ere eee aT) 41.87 6 Sulphatomiding 7, Sulphaguanidine oe ee 8, Sulphaphenazole : acne, 9. Other Sulpia Drugs TT XI Puamins: : 1 VilaminA oe MMU 2. vitamin B12 : Kegs. 3. Vitamin © ae oe 5 4. Nicetinieacidjamide ee 0.98 5. Vitamin B.2 cere eeCee nT) 6, Vitamin B-t : T 1 Kes, 8. Vitamin BG ‘ ee Kee ®. Folic Acid. ry 1 XUll, Other Drugs: 1. Calcium glucoaate/Lactobionate T Ferrous gluconate T 43. Nikethamide 5 T 0.35 4. Diethy!carbamazine citrate r 5, Meprobemate foe r 6. Amidopyzin T 7, Phenobarbitone Tr 8. Pothidine Hel. . Ks. 9. Dipienyl MyJramtine He. T $56 15.328 027 9.03 14.008 13.38 75.236 114,32 . 27.816 4s 5.22 ots 0.213 13st 6Lals 18.142 3. 3.108 NA 107.71 19.06 48.27 02.36 23.5 43.7 93.79 31.47 1331 130.14 25.651 8.600 4.83 318 56 17 126 149 86 sot 1s7 6 -20 7 141 134 1.431 5.39 2 0.40 t55 2 8 n Nil. 3 4 198 3.4 o4as 11.30 228.81 37.82 71.88 53.45 265.97 38.1 41.38 178.68 261.58 01.40 124 21.39 75.99Ast suat ¥ ING THE RAPORTS OF RULK DXUGS DURING 1971-72 TO 173 74 WHICH ARE ALSO. MANUFACTURND INDIGENOUSLY STATEMENT SHON raptor Hast 17 w9r2-73 No. ounting —————____— Unit Quantity Value Quantity Value Quantity in Rs ins, 1. Pethidine Hel 303.784 70,101 67,817 183.39 876.277 2 Procaine Hul. 23,781 6.86,794 454015 15,633 353.851 3. Anatgin (metamizol) 1,30.586 56,65,850 5489,223 219,994 64.78,675 4. Phenyl Butazone 22209.2 100.878 724,776.01 983.577" 1,180.26, 168,208 5. Oxy Phentutazone 2366.3 625843 5.919.215 A028. 28, 67,183 6. Emetine a - = = = 309 $228 7. Phewscetia f 13,650 1.105386 ~ = 7 = 8. Chloramphenicol Q 65,638 16878618 —64,470.5—OLLLS47* 41,009 49,24,126 9. Chloramplienicol Palmitate, i018 STIR 35652 49,0,112 20.390 26,582,604 10, Chloramphenicol Succinate 400 180,860 400 81295 3,100 10,46,008 11, Chlor-tetracyctine 55 30,992 47.6 23316 180 66,196 12. Oxy-tetrcyetine sh190 10787567 1,817.3 283453 NA ail 13, Tetracycline Hel * 4365.5 1,16.41,190 20,126 8615109 $4,025, 73,59,808 14, Penicillin G Sodiur M.U. 1,00,00,000 19.95.9865 Nil Nil Nil Nil 15, Penicillin G Potassium 3,00,00,000 3919,674 99,90080 NTs) 518,149 vasas 36, streptomycin Sulphur Kgs 83.7034 884 9.205.746 96495 ——51,945. 319 17. Neomycin 5 a 4.61 | 1,79,52 6167 778,007 4,858,025 15,153,919 18. Exythromycin (Bulk) 277.82 1,18,61,613 21 1,14,10,028 "9.097 65,39 081 419, Ampicilin (Bulk) 2.776038, 21003,551 6837.5. AT,13,379 24,592.31 1,69,69,030 20. avulin Cystallin Plain. MU. LM 20,75,640 152,09) 7950111 15.0026 738,856 DL Torbutamide . Kgs 188 2.9094 6201 155,662 1688 ‘35.196 22. Chlorprepamide 44455 12,156 198 1,27.612 756 50,66 23. Phenformin Hel 1,388,052 2B 29,55,29 448,689 2,584.05, 349349 24. Choroquin’s Salts (Bulk). 52,688.53 768,809 99,335.64 1.270597 AS05217 6,3 2OE 25. Mepyramine Maleate : 7.3 S798 36L 54.606 336 109,030 26. Diphenydramine Hel 5 1,718 95,547 1,835.62 73,830 140 15,416 21, Promethazine (Base & Hel), m3 26,159 535 83,028 bs 2597 28. Promethazine DB. Chlore- Theophylinate sw 9s 27603 26.28 6600 23.85 9.203 29, Isoniazid (IN) a 3.100 93,000 1,300 32,500 Nil Ni GAYPAS & Its sats : 11,000 8,89,903 a a “ Digoxin Gins. 3.433 1537122201 103,797 3,582 153879 Caffeine Kgs 57150 1438277 25,000 800,93 Nil Nil Hydrochlocthiazide » 25 209 63.81 3.510 09 2000 33. Spironolactone : 18.5 21992 1 10.834 2 24990 24. Prednisone Lo Nil Nil 9.68 44095 1,650 5.303 35. Predaisolone . . . Nil Nit 20918 86,733 q Nil 36. Dexamethasone * sods 3799,04 37.598 20.22.9487 909,858, 32,19,810 37. Ethiswrone . 188.62 472,615 238.43 422,143 246.317 8,53.111 38. Hydrocortisone . 89.48 3,67,564 100.6 3,068,155 23.8 35297 39. A dreialine & is Salts ji 20,83 1,00,264 2 25,846 0 35557 40. Diptheria Antitoxin Bulk), 2a 100112 1177-46 403,171 848.590 233295 4L Tetanus Antitoxia (Bulk). 3,529.5 8963 3077.4 738.855 810 193,600 42, Phthalyl Sulphacetamide 4, 1g2s 84552. 2,300 ‘9301 2,000 97,379 448. $s 56. 30 38 9. a. a ulnabeoke sacsinyl $phacta’ se Suiphagaimadine Sulohadimidine Sulphadiszine Sulphasounitine ) Suiphapironaeane . Sulpbamethizote |. Meprobamate 9. Pronlorpoxzine Maleate & Ethane Sulphate Folic Acid . Penthenal ‘Nicotinamide Vitamin BE? Vitamin B2 aan Riboflavin $ Phos-So.ian Vitamin B12, Vitaosin C Vitamin K. Viiamia P Phonoberbitone 5. Phenobarbitone Sodan 1. Ephedrine Metronidazole Nikethamide (ermine) Pipseazine Hexabyteate Diazepam Calcium Lactate Caloropromazine Hel ‘Guamsthidine Sulphate . Clofibeate s 3267 200 50.000 148,500 . 43.410 : 1,120 ” 1454s 3.525 : 25 1.612.921 3381.3 . 465.7 35,718.88 169.7 12 a Gms. Ks, MV Kes R020 . 95.5 . 1153.85 ® 4.325 2,207.17 ‘i 10 o 668.38 28,2563 6.16087 7347 319,473, 1447 9,36,666 715.405 22,567 5698,913 4.70033 7.77033 102,379 3393.350 oe 798,160 209 782847 16,073 UIs 1128409 831,183 12380 sas: 26,785, 13859 sath 20337 Press 1360 306,082 2915 sil 00,859 124,900 1035 54.909 8.687 12357 35.4 Nil 6,758 22,160 14216 5.189 11,76,558 30:90, 760 48 3,770.5 130, 3,730 9,687.40 (6255.3 187.5 6.800 638.05, 1,293.2 3.75 3.975 1.836,50 1,319 375 nit 16.16.76: 29,68,011 55,385 7,980 19,10,130 9.11348 25,958 Nil 642,116 10,12,137 16,9012 11001,399 Nil Nil Lon o1494 33371 445,791 ait 461,889 9.987 $8022 1,598 18,5257 23 20366 309,835 3.782 502,653 x 3 1.30 7195 Nil 6,676.5 11,250 os 1.77 3.95,000 188,109 5.629.008 Rs 19 5,265 Nil Nil 967.425 25,583.78 2,388 1.05,950 3,110.38 1408.63 Nil Nat 2455.1 10 5210.3 Nit (9.550 10s 10.78.38 Nil 9.63452 201,974 699961 4273 ne 2,18,384 793,013 Nil 2495,213 2415922 3,70,633 234,973 112.64,591 37.299 8,¢0,683 2499 751,890 Nit Nil 31,9701 113311 837.685, 769,351 798,295 Nil Nit 393,834 18,201 naaJ. Anal - Oxy-phanyL-butazone . Chloramphenicol & estes . Tetracycline/Fel. ‘Streptamycine Sulphate Griseofulvin 5. Framycetin . Erythromycin. - Choroquin/Satts . Ergot alkaloids 52, Dexamethasone 13, Triaminolore 14. Nor-ethysterone 15. Phihaty! Sulphathiazole 16, Sulphaguanidine 17, Sulphagimidine 3. Sulphamethoxy Pyridazine >. Thioridazine (Meer) ). Pentothenates, Nalea itamin BI . Vitamin B2 Vitamin 86 Vitamin © 5. Polyvinyl Pynolidone 26, Ephedrine. 27. Ethionamide 28, Glucose anhydrous 29. Twoxuprine 30, Methyl Dopa 31, Metronidazole 1 2. 3. 4 5. 6 7. Neonyein 8 9. 10. n, 33. Ampicitin 34. Tsoptine 35, Centanycia Sulphate 36, Nogestrol 37. Pyrazinamide 38, Purinetho! - Pethidine Hel 2. Procaine Hel 3. Diloxanide;Furoate ANNEXURE (Chapter WP 1) Be. 10 fues Empors escendin Durie worst Quantity 219.09. 9.85 6s 3 S198 4.82 4.46 0.608 ° 48.05 18k 90, 08k 39.8 19, 85k, 121.99 “ ans 1.2 7 25,99 nor between Rs, S and Re, 10 lars Daring 1918-74 6 28,“4. Cyloserine D Tartrate 5, Cyclophosphamie 6 Insulin, Plain 7. Calorphenirusins msate . Aminophyltine 9, Eihyste 10, Diosaganin 11, Sulpha-merazine 12, Sulphasomidine 13, Sulphamethizole 14, Penthenol 15, Vitamin E 16. Vitamin P 17, Avanyrezine: 18, Bisumuth Salts 19, Dydrogesterone 20, Furazoldoné 21, Piperazine Hexahydrate 22, Diazepam 23, Furosemide 24, Thiabendazole 25, Doxyeycline 26. L-Dopa 15049, 541.6318 Vaccire Yellow Fever 12 ‘541.6329 Bacterial Vacrine nies 453 90156 541.6331 Bacteriological Products n.c.s. 10 $41,7001 Ayurvedic & Unani Modicines 1536.4 1959.5 5193.1 1 1'541.7002 Homeopathic Medicines 668 DRE OO 25617003 Acctarsol BLP.C. (Stovarsol), 65

You might also like

• PHM PCH English

  

  Document9 pages

  PHM PCH English

  lalit823187

  No ratings yet
• NHA1 Booklet - A World Where We Matter

  

  Document70 pages

  NHA1 Booklet - A World Where We Matter

  lalit823187

  No ratings yet
• Task Force On Conservation and Sustainable Use of Medicinal Plants Report 2000

  

  Document194 pages

  Task Force On Conservation and Sustainable Use of Medicinal Plants Report 2000

  lalit823187

  No ratings yet
• • Magazines
  • Podcasts
  • Sheet music
• Mudaliar Committee Report 1961

  

  Document319 pages

  Mudaliar Committee Report 1961

  lalit823187

  100% (1)
• MFC Anthology: in Search of Diagnosis

  

  Document95 pages

  MFC Anthology: in Search of Diagnosis

  lalit823187

  No ratings yet
• Mehta Committee Report 1983

  

  Document110 pages

  Mehta Committee Report 1983

  lalit823187

  100% (1)
• Working Group On Health For All Report 1981

  

  Document121 pages

  Working Group On Health For All Report 1981

  lalit823187

  No ratings yet
• MFC Anthology: Medical Education Re-Examined

  

  Document116 pages

  MFC Anthology: Medical Education Re-Examined

  lalit823187

  No ratings yet
• National Commission On Macro Economics and Health

  

  Document192 pages

  National Commission On Macro Economics and Health

  Apollo Institute of Hospital Administration

  No ratings yet
• Udupa Committee Report 1959

  

  Document195 pages

  Udupa Committee Report 1959

  lalit823187

  No ratings yet
• Working Group On Population Policy Report 1980

  

  Document59 pages

  Working Group On Population Policy Report 1980

  lalit823187

  No ratings yet
• Kartar Singh Committee Report 1973

  

  Document81 pages

  Kartar Singh Committee Report 1973

  lalit823187

  33% (3)
• Mashelkar Committee Report

  

  Document157 pages

  Mashelkar Committee Report

  Devidutt Gharai

  No ratings yet
• Consultative Committee of Experts On Revised Strategy For NMEP Report 1974

  

  Document24 pages

  Consultative Committee of Experts On Revised Strategy For NMEP Report 1974

  lalit823187

  No ratings yet
• Group On Health Education and Support Manpower Report 1975

  

  Document42 pages

  Group On Health Education and Support Manpower Report 1975

  lalit823187

  No ratings yet
• Chadha Committee Report 1963

  

  Document47 pages

  Chadha Committee Report 1963

  lalit823187

  50% (2)
• High Power Committee On Nursing and Nursing Profession Report 1989

  

  Document143 pages

  High Power Committee On Nursing and Nursing Profession Report 1989

  lalit823187

  No ratings yet
• Mukerji Committee Report 1966

  

  Document47 pages

  Mukerji Committee Report 1966

  lalit823187

  100% (1)
• Bhore Committee Report 1946 Vol 2

  

  Document434 pages

  Bhore Committee Report 1946 Vol 2

  lalit823187

  100% (1)
• Bajaj Committee Report 1987

  

  Document91 pages

  Bajaj Committee Report 1987

  lalit823187

  100% (1)
• Bhore Committee Report 1946 Vol 1

  

  Document205 pages

  Bhore Committee Report 1946 Vol 1

  lalit823187

  100% (1)
• NHA2 Booklet - HIV-AID Treatment Access

  

  Document56 pages

  NHA2 Booklet - HIV-AID Treatment Access

  lalit823187

  No ratings yet
• Bajaj Committee Report 1996

  

  Document267 pages

  Bajaj Committee Report 1996

  lalit823187

  No ratings yet
• NHA2 Booklet - New Technologies in Public Health

  

  Document49 pages

  NHA2 Booklet - New Technologies in Public Health

  lalit823187

  No ratings yet
• NHA2 Booklet - Campaign Issues in Child Health

  

  Document62 pages

  NHA2 Booklet - Campaign Issues in Child Health

  lalit823187

  No ratings yet
• Bhore Committee Report 1946 Vol 3

  

  Document315 pages

  Bhore Committee Report 1946 Vol 3

  lalit823187

  No ratings yet
• Health System in India PDF

  

  Document87 pages

  Health System in India PDF

  Dr. Mohammad Noor Alam

  No ratings yet
• Globalization and Its Impact On Health in India

  

  Document45 pages

  Globalization and Its Impact On Health in India

  drvikasbajpai

  No ratings yet
• The Subtle Art of Not Giving a F*ck: A Counterintuitive Approach to Living a Good Life

  

  From Everand

  The Subtle Art of Not Giving a F*ck: A Counterintuitive Approach to Living a Good Life

  Mark Manson

  Rating: 4 out of 5 stars

  4/5 (5794)
• The Little Book of Hygge: Danish Secrets to Happy Living

  

  From Everand

  The Little Book of Hygge: Danish Secrets to Happy Living

  Meik Wiking

  Rating: 3.5 out of 5 stars

  3.5/5 (399)
• A Heartbreaking Work Of Staggering Genius: A Memoir Based on a True Story

  

  From Everand

  A Heartbreaking Work Of Staggering Genius: A Memoir Based on a True Story

  Dave Eggers

  Rating: 3.5 out of 5 stars

  3.5/5 (231)
• Hidden Figures: The American Dream and the Untold Story of the Black Women Mathematicians Who Helped Win the Space Race

  

  From Everand

  Hidden Figures: The American Dream and the Untold Story of the Black Women Mathematicians Who Helped Win the Space Race

  Margot Lee Shetterly

  Rating: 4 out of 5 stars

  4/5 (894)
• The Yellow House: A Memoir (2019 National Book Award Winner)

  

  From Everand

  The Yellow House: A Memoir (2019 National Book Award Winner)

  Sarah M. Broom

  Rating: 4 out of 5 stars

  4/5 (98)
• Shoe Dog: A Memoir by the Creator of Nike

  

  From Everand

  Shoe Dog: A Memoir by the Creator of Nike

  Phil Knight

  Rating: 4.5 out of 5 stars

  4.5/5 (537)
• Elon Musk: Tesla, SpaceX, and the Quest for a Fantastic Future

  

  From Everand

  Elon Musk: Tesla, SpaceX, and the Quest for a Fantastic Future

  Ashlee Vance

  Rating: 4.5 out of 5 stars

  4.5/5 (474)
• Never Split the Difference: Negotiating As If Your Life Depended On It

  

  From Everand

  Never Split the Difference: Negotiating As If Your Life Depended On It

  Chris Voss

  Rating: 4.5 out of 5 stars

  4.5/5 (838)
• Grit: The Power of Passion and Perseverance

  

  From Everand

  Grit: The Power of Passion and Perseverance

  Angela Duckworth

  Rating: 4 out of 5 stars

  4/5 (587)
• Devil in the Grove: Thurgood Marshall, the Groveland Boys, and the Dawn of a New America

  

  From Everand

  Devil in the Grove: Thurgood Marshall, the Groveland Boys, and the Dawn of a New America

  Gilbert King

  Rating: 4.5 out of 5 stars

  4.5/5 (265)
• Yes Please

  

  From Everand

  Yes Please

  Amy Poehler

  Rating: 4 out of 5 stars

  4/5 (1891)
• Angela's Ashes: A Memoir

  

  From Everand

  Angela's Ashes: A Memoir

  Frank McCourt

  Rating: 4.5 out of 5 stars

  4.5/5 (440)
• The Emperor of All Maladies: A Biography of Cancer

  

  From Everand

  The Emperor of All Maladies: A Biography of Cancer

  Siddhartha Mukherjee

  Rating: 4.5 out of 5 stars

  4.5/5 (271)
• On Fire: The (Burning) Case for a Green New Deal

  

  From Everand

  On Fire: The (Burning) Case for a Green New Deal

  Naomi Klein

  Rating: 4 out of 5 stars

  4/5 (73)
• The Hard Thing About Hard Things: Building a Business When There Are No Easy Answers

  

  From Everand

  The Hard Thing About Hard Things: Building a Business When There Are No Easy Answers

  Ben Horowitz

  Rating: 4.5 out of 5 stars

  4.5/5 (344)
• Team of Rivals: The Political Genius of Abraham Lincoln

  

  From Everand

  Team of Rivals: The Political Genius of Abraham Lincoln

  Doris Kearns Goodwin

  Rating: 4.5 out of 5 stars

  4.5/5 (234)
• Fear: Trump in the White House

  

  From Everand

  Fear: Trump in the White House

  Bob Woodward

  Rating: 3.5 out of 5 stars

  3.5/5 (738)
• The Glass Castle: A Memoir

  

  From Everand

  The Glass Castle: A Memoir

  Jeannette Walls

  Rating: 4.5 out of 5 stars

  4.5/5 (1712)
• Rise of ISIS: A Threat We Can't Ignore

  

  From Everand

  Rise of ISIS: A Threat We Can't Ignore

  Jay Sekulow

  Rating: 3.5 out of 5 stars

  3.5/5 (137)
• Principles: Life and Work

  

  From Everand

  Principles: Life and Work

  Ray Dalio

  Rating: 4 out of 5 stars

  4/5 (599)
• The Unwinding: An Inner History of the New America

  

  From Everand

  The Unwinding: An Inner History of the New America

  George Packer

  Rating: 4 out of 5 stars

  4/5 (45)
• The World Is Flat 3.0: A Brief History of the Twenty-first Century

  

  From Everand

  The World Is Flat 3.0: A Brief History of the Twenty-first Century

  Thomas L. Friedman

  Rating: 3.5 out of 5 stars

  3.5/5 (2219)
• Steve Jobs

  

  From Everand

  Steve Jobs

  Walter Isaacson

  Rating: 4.5 out of 5 stars

  4.5/5 (806)
• John Adams

  

  From Everand

  John Adams

  David McCullough

  Rating: 4.5 out of 5 stars

  4.5/5 (2409)
• The Gifts of Imperfection: Let Go of Who You Think You're Supposed to Be and Embrace Who You Are

  

  From Everand

  The Gifts of Imperfection: Let Go of Who You Think You're Supposed to Be and Embrace Who You Are

  Brené Brown

  Rating: 4 out of 5 stars

  4/5 (1090)
• Bad Feminist: Essays

  

  From Everand

  Bad Feminist: Essays

  Roxane Gay

  Rating: 4 out of 5 stars

  4/5 (1015)
• The Outsider: A Novel

  

  From Everand

  The Outsider: A Novel

  Stephen King

  Rating: 4 out of 5 stars

  4/5 (1839)
• Brooklyn: A Novel

  

  From Everand

  Brooklyn: A Novel

  Colm Toibin

  Rating: 3.5 out of 5 stars

  3.5/5 (1937)
• The Sympathizer: A Novel (Pulitzer Prize for Fiction)

  

  From Everand

  The Sympathizer: A Novel (Pulitzer Prize for Fiction)

  Viet Thanh Nguyen

  Rating: 4.5 out of 5 stars

  4.5/5 (119)
• A Man Called Ove: A Novel

  

  From Everand

  A Man Called Ove: A Novel

  Fredrik Backman

  Rating: 4.5 out of 5 stars

  4.5/5 (4609)
• The Light Between Oceans: A Novel

  

  From Everand

  The Light Between Oceans: A Novel

  M.L. Stedman

  Rating: 4.5 out of 5 stars

  4.5/5 (789)
• The Woman in Cabin 10

  

  From Everand

  The Woman in Cabin 10

  Ruth Ware

  Rating: 3.5 out of 5 stars

  3.5/5 (2322)
• Manhattan Beach: A Novel

  

  From Everand

  Manhattan Beach: A Novel

  Jennifer Egan

  Rating: 3.5 out of 5 stars

  3.5/5 (792)
• The Perks of Being a Wallflower

  

  From Everand

  The Perks of Being a Wallflower

  Stephen Chbosky

  Rating: 4.5 out of 5 stars

  4.5/5 (2099)
• Wolf Hall: A Novel

  

  From Everand

  Wolf Hall: A Novel

  Hilary Mantel

  Rating: 4 out of 5 stars

  4/5 (3811)
• Little Women

  

  From Everand

  Little Women

  Louisa May Alcott

  Rating: 4 out of 5 stars

  4/5 (104)
• The Art of Racing in the Rain: A Novel

  

  From Everand

  The Art of Racing in the Rain: A Novel

  Garth Stein

  Rating: 4 out of 5 stars

  4/5 (4200)
• Sing, Unburied, Sing: A Novel

  

  From Everand

  Sing, Unburied, Sing: A Novel

  Jesmyn Ward

  Rating: 4 out of 5 stars

  4/5 (1103)
• A Tree Grows in Brooklyn

  

  From Everand

  A Tree Grows in Brooklyn

  Betty Smith

  Rating: 4.5 out of 5 stars

  4.5/5 (1929)
• The Constant Gardener: A Novel

  

  From Everand

  The Constant Gardener: A Novel

  John le Carre

  Rating: 3.5 out of 5 stars

  3.5/5 (104)
• Her Body and Other Parties: Stories

  

  From Everand

  Her Body and Other Parties: Stories

  Carmen Maria Machado

  Rating: 4 out of 5 stars

  4/5 (821)